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ABSTRACT 
In the battle between the immune system and cancer, tolerance mechanisms otherwise protective 
against autoimmunity, are exploited to halt the anti-tumor immune response. In this model, 
tumors turn distinct parts of the immune system against each other; suppressive cells such as 
regulatory T cells (Tregs) are hijacked to obstruct effector lymphocytes in their attempt to 
eradicate the tumor. We explored the effects of this immunomodulation on Tregs, effector T cells 
(Teff) and B cells in patients with urinary bladder cancer (UBC) and examined what impact 
chemotherapy has on this process. 
Puzzled by our previous finding of tumor-infiltrating Tregs to correlate to a favorable prognosis 
in patients with UBC, we sought to corroborate our results and ensure that we had not mistaken 
Teff cells for Treg cells. This was not the case, since we demonstrated tumor-infiltrating 
CD4+FOXP3+ T cells to be phenotypically, functionally and epigenetically stably committed 
Tregs. In search for a mechanistic explanation to the apparent favorable role of Tregs in UBC, we 
found this cell population to mediate suppression of the prometastatic factor MMP2, produced by 
M2 macrophages and UBC cells at the invasive front of the tumor microenvironment (TME). 
This finding supports the model where Tregs, by controlling inflammation, may benefit patients 
with inflammation-driven cancers.  
In our initial investigation of chemotherapeutic effects on lymphocytes, we found Doxorubicin 
to enhance the antigen presenting ability of B cells, with a subsequent increased activation of 
CD4+ T cells. This effect was mediated by an increased expression of the co-stimulatory molecule 
CD86, together with an altered cytokine profile including IL-10 and TNFα. The findings were 
translatable to the clinical setting, since CD86 expression was increased on circulating B cells of 
patients treated with Doxorubicin-containing neoadjuvant chemotherapy (NAC). When further 
evaluating the effects of chemotherapy on the T cell compartment, we changed scenery from 
peripheral blood to the Sentinel node (SN). CD8+ Teff exhaustion was demonstrated to be reduced 
after NAC treatment, while cytotoxicity was increased. In complete responders (CRs) to NAC, 
these cells were functionally and epigenetically committed effectors. For CD4+ Teff cells, tumor-
specific reactivity was observed after NAC. In contrast, Tregs were attenuated by NAC in a dose-
dependent manner with decreased frequency and reduced effector molecule expression. Also, 
CRs had higher Teff to activated Treg ratio, promoting antitumoral T cell activation. 
In our further examination of SN T cells we wondered if their proteome was altered by the tumor. 
We found growth- and immune signaling to be up-regulated in SN Tregs. Most significantly, 
Interleukin (IL)-16 was identified as central in SN Treg signaling, Furthermore, direct contact 
with tumoral factors increased Treg IL-16 processing into its bioactive forms and this effect was 
mediated by active caspase-3.  
In conclusion, the adaptive arm of the immune system in the TME is heavily modulated in patients 
with UBC, where NAC contributes with substantial positive effects on this system. The observed 
suppression of tumor promoting inflammation by Tregs, manifested by inhibition of M2 
macrophage functions, suggests the view of Tregs as a clear-cut negative force in tumor immunity 
to be a reductionistic and unfortunate vision.   
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1 INTRODUCTION 
The evolutionary emergence of vertebrate predators coincided with two macroevolutionary 
events, believed to have contributed to the genesis of the adaptive immune system (AIS) (1). 
These events occurred approximately 500 million years ago in jawed fish, which equipped them 
with diversifying antigen receptors on lymphocytes and thus a specific, yet incredibly diverse 
defense system against a myriad of pathogens. The major advantage of this feature at that time, 
has been attributed to the extraordinary ability of the AIS to protect offspring. 
This advancement, which was enabled through somatic recombination, came at a cost, as it 
necessitates the generation of tolerance to self to prevent autoimmunity. To this end, regulatory 
T cells (Tregs), a cell population with the job to maintain immune homeostasis (2), were 
developed. The implications of this self-tolerance concept on the immune systems’ attempt to 
protect the organism against cancer, is a central theme of this thesis.  
The development of cancer, oncogenesis, is initiated by mutations that activate oncogenic drivers 
(3). This process is accompanied with activation of tumor-promoting genes or inactivation of 
tumor-suppressive genes, or both thereof. In many cancers, the process of oncogenesis results in 
an accumulation of mutations due to the selective advantage of cells with an unstable genome as 
it fosters proliferative fitness. In this way, mutations compile in an accelerating manner, rendering 
the tumor genome highly diverse. This diversity, again, comes at a price: the further a cancer cell 
diverges from its normal state, the more prone it is to be recognized as foreign by the AIS.  
The notion that cancer may be visible to the immune system, i.e., immunogenic, was considered 
already by William Coley, a surgeon who linked the occurrence of postoperative infection with 
improved clinical outcomes for people with cancer. Today, the capacity of the immune system to 
eliminate tumors is indisputable, owing to the unprecedented success of cancer immunotherapies, 
including so called ”checkpoint inhibitors” and ”CAR T cells”, which both mediate long-lasting 
tumor responses in people with a variety of cancers (4, 5).  
Yet, far from all people respond to these novel treatments and all tumors that de facto arise in 
immunocompetent organisms are living examples of a failed anti-tumor immune response. The 
consensus view is that these failures generally result from the capacity of the tumor to escape 
recognition by the immune system, which the tumor accomplishes by hijacking the otherwise 
beneficial self-tolerance machinery, including the Treg cell population (6). The recognition that 
such tumor immune escape is a critical hurdle in cancer immunotherapies, and in tumor immunity 
at large, has sparked an intense search for strategies to target these escape mechanisms. In this 
pursuit, standard chemotherapy has risen like a phoenix from the ashes.  
The mechanisms behind chemotherapy efficacy are currently being reevaluated, with an 
increased awareness of their immune stimulatory effects. This insight is the basis for the second 
central theme of this work, where we explore what impact standard chemotherapy has on the 
intricate interplay between the tumor and the AIS.   
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1.1 OVERVIEW OF URINARY BLADDER CANCER 
The term “urinary bladder cancer” (UBC) is unspecific and, in strict sense, even comprises 
metastasized tumors from other primary organs. However, for the sake of simplicity, in this thesis 
UBC refers to tumors that originate from the transitional epithelium of the urinary bladder, i.e. 
urothelial urinary bladder cancer. 
Fortunately, the knowledge and management of UBC is continuously growing more sophisticated 
with new diagnostic tools, new UBC subtypes being defined and novel treatment protocols 
surfacing into the clinic. The following passage is an attempt to, in a condensed format, describe 
the clinical management and inherent immunological aspects of this malignancy.  
1.1.1 Epidemiology, Diagnostic evaluation and Classification  
This year, ≈165,000 persons will die from UBC and another 430,000 new cases will appear on 
the globe (7). This makes UBC the 11th most commonly diagnosed cancer worldwide and the 7th 
among men, reflecting a strong sex bias with a 3:1 male-female distribution (8). In the European 
Union, UBC was the 9th most common cause of cancer death in 2012 and the mortality remains 
high, although a modest decline has been reported for in the industrialized world (7). The 
incidence rate varies across countries, likely due to differences in exposure to the major risk 
factors such as tobacco smoking.  
More than 90 % of all UBCs are of urothelial origin, and the remainders mainly comprise 
squamous cell- or adenocarcinomas. At the time of diagnosis, approximately 75 % of the patients 
present with non-muscle-invasive bladder cancer (NMIBC), which is defined as disease confined 
to the mucosa (stage Ta and Cancer in situ (CIS)) or submucosa (stage T1). Although these three 
types of lesions indeed are non-muscle-invasive, T1 and CIS lesions are distinct from Ta lesions 
since they have a high potential to become invasive (≈50 % of CIS lesions progress if left 
untreated) (9). Thus, accurate histopathologic assessment and diagnosis is crucial for correct 
clinical management which differs drastically between Muscle-invasive bladder cancer (MIBC) 
and NMIBC. The diagnostic work-up includes, but is not limited to, physical examination, 
imaging and transurethral resection of the bladder tumor (TURBT) with subsequent histological 
evaluation. In patients with confirmed MIBC, Computer tomography (CT) of the chest, abdomen 
and pelvis is currently used for staging due to yet insufficient data supporting advantages of FDG-
PET/CT (8).  
Using the acquired information from these modalities, UBCs are subcategorized according to the 
Tumor, Node, Metastasis (TNM) system as detailed in Table I. The TNM stage is coupled with 
the histological differentiation grade (according to the World Health Organization classification 
system) and this categorization guides the choice of treatment. Pre-treatment (e.g. cystectomy), 
the TNM is labeled “clinical TNM” (cTNM) and is partly based on data from the clinical 
examination whereas post-cystectomy, TNM is termed “pathological TNM” (pTNM), which is 
based mainly on histopathological data of the excised urinary bladder and lymph nodes. 
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Table 1: TNM classification of urinary bladder cancer  
Modified from the European Association of Urology (EAU) Guidelines on  
Muscle-invasive and Metastatic Bladder Cancer 
 
 
 
 
 
 
 
 
 
 
 
 
´ 
It should be stressed, that there are major ongoing efforts to refine the subgrouping of patients in 
order to better predict the most suitable treatment for a given patient. In this pursuit, five new 
distinct MIBC subtypes (luminal-papillary, luminal infiltrated, luminal, basal/squamous, and 
neuronal) have been identified through next-generation sequencing (NGS) of the whole exome 
as well as gene expression analysis, an extensive and seminal work provided by The Cancer 
Genome Atlas Research Network (10). These subtypes do not necessarily reflect the 
histopathological appearance of UBC, but are rather associated with specific pathway alterations 
and other biological features.  
1.1.2 Treatment Modalities  
For Ta tumors, the TURBT itself may be sufficient for complete eradication. However, in NMIBC 
cases at high risk of recurrence or progression, intravesical treatment with live attenuated 
Mycobacterium Bovis, often referred to as Bacillus Calmette-Guérin (BCG), is the gold standard. 
BCG instillation induces a tumor-specific effect with a complete response rate of 55–65% for 
high-risk papillary tumors and 70–75% for CIS (11). As such, BCG is the most successful cancer 
immunotherapy at use to date and has proven difficult to excel ever since its first use for UBC in 
the 1970s (first available as a tuberculosis vaccination already in the 1920s). The mechanism of 
T - Primary Tumor 
Tx Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Ta Non-invasive papillary carcinoma 
Tis Carcinoma in situ: “flat tumor” 
T1 Tumor invades subepithelial connective tissue 
T2 Tumor invades muscle 
T2a Tumor invades superficial muscle (inner half) 
T2b Tumor invades deep muscle (outer half) 
T3 Tumor invades perivesical tissue: 
T3a microscopically 
T3b macroscopically (extravesical mass) 
T4 Tumor invades any of the following: prostate stroma, seminal vesicles, 
                        uterus, vagina, pelvic wall, abdominal wall  
  T4a Tumor invades prostate stroma, seminal vesicles,  
                                               uterus, or vagina 
  T4b Tumor invades pelvic wall or abdominal wall 
N - Regional Lymph Nodes 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph-node metastasis 
N1 Metastasis in a single lymph node in the true pelvis (hypogastric,  
                        obturator, external iliac, or presacral) 
N2 Metastasis in multiple lymph nodes in the true pelvis (hypogastric,  
                        obturator, external iliac, or presacral) 
N3 Metastasis in common iliac lymph node(s) 
M – Distant Metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
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action is not fully mapped, however data suggest that the bacterium is internalized into the 
urothelial cells through macropinocytosis, processed, and presented on major histocompatibility 
complex (MHC) class II pocket and intracellular adhesion molecule 1 (ICAM-1) (12, 13). 
Although incompletely understood, it is well substantiated that the effect of BCG is dependent of 
a T helper (Th) 1 cell immune response. For instance, a T cell requirement was demonstrated in 
athymic nude mice bearing bladder tumors, who failed to mount an anti-tumor response following 
BCG instillation (14). These notions emphasize the immunogenic nature of UBC and indicate 
immunotherapy as a possible approach also in the late stages of this cancer (although BCG 
specifically is not effective for MIBC).  
Further underscoring UBC as an immunogenic malignancy is its pronounced mutational load, 
potentially raising an abundance of tumor antigens enabling T cell responses. Indeed, checkpoint 
inhibition has proven beneficial for a subset of MIBC patients and mutation burden was reported 
to be an independent predictive factor for response to such immunotherapy (15). Finally, the 
integral role of the immune system in bladder cancer at large is manifested by the well-established 
relationship between inflammatory settings like schistosomiasis infection (in squamous cell 
carcinoma) and other chronic urinary tract infections and the development of this malignancy 
(16). 
Immunotherapy against MIBC is a recent progress and, yet, conventional cancer therapies remain 
the gold standard for this patient category. In essence, following TURBT, fit patients receive 
cisplatin-containing neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) which 
includes removal of the regional lymph nodes along with the bladder. Despite these efforts, half 
of the patients will die from their disease within five years from diagnosis (17) and in the presence 
of lymph node metastases the 3-year mortality is 75% (unpublished data from the Nordic 
Cystectomy Studies). Thus, there is an urgent need for new and improved treatments. 
Meta-analyses of RCTs with long term follow up unanimously demonstrate a 5-8 % survival 
benefit at 5 years in NAC-treated MIBC patients (17-19). Moreover, patients with complete 
response (pT0N0M0 stage) to NAC have an absolute risk reduction of 31.1% for death (18). Of 
note, there is only evidence of a meaningful therapeutic benefit for NAC regimens containing 
cisplatin combined with at least one additional chemotherapeutic agent. Among the commonly 
used such regimens is the combination of methotrexate, vinblastine, adriamycin and cisplatin 
(MVAC). In addition to NAC, pre-operative radiotherapy for operable MIBC may be offered 
since there is data supporting an increased chance of down-staging, however is not part of the 
clinical routine in Sweden (19) 
Adjuvant chemotherapy is only recommended to pT3/4 and/or pN+ patients and only if no NAC 
has been given (8). In the case of further metastatic disease, in Sweden, the standard procedure is 
that additional chemotherapy is used only as a palliative treatment when pN+ patients (or pM+ 
patients) develop symptomatic progression. For such second-line treatment, the objective 
response rate is about 10 %.  
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Because of the dismal prognosis, the dawning of immunotherapy to be used for this patient 
category has sparked immense enthusiasm. For instance, atezolizumab, was the first checkpoint 
inhibitor that targets the programmed cell death protein 1 Ligand (PD-L1), to be approved by the 
US food and drug administration. The approval was limited for use as a second-line treatment 
and based on a phase II trial demonstrating an overall response rate of 15 % in patients with 
inoperable locally advanced or metastatic BC refractory to cisplatin-based chemotherapy (15). In 
patients with high PD-L1 expression, the response rate was 27 %. After demonstrating 
encouraging response rates and increased survival in the first-line setting for cisplatin-ineligible 
patients, atezolizumab was granted approval also for this patient category (20). Moreover, 
additional immune checkpoint inhibitors have been approved for the use in UBC and there are 
currently numerous ongoing late-stage trials also for other immunotherapies, including adoptive 
T cell therapy (ACT) and cancer vaccines. 
Although immunotherapy against MIBC is promising, many challenges remain to be tackled, as 
highlighted by the recent phase 3 IMvigor211 trial (21). In the trial, atezolizumab did not meet 
its primary endpoint of improved survival compared with chemotherapy in the setting of 
metastatic UBC. One factor that might have influenced this outcome is that the proportion of 
patients sensitive to checkpoint blockers might be lower than previously appreciated. Hence, the 
result emphasizes the importance of proper patient selection and the need of better predictive 
biomarkers. In this pursuit, it appears critical to determine the immune contexture which, 
simplified, could be defined as the spatial distribution and organization of the leukocyte infiltrate 
of the tumor (reviewed in (22)). NGS is an additional promising tool for guidance in treatment 
decisions. For instance, NGS of more than 100 NMIBC tumors demonstrated a correlation 
between mutations in the ARID1A gene and an increased risk of recurrence after BCG treatment 
(23). Additionally, a single-sample genomic subtyping classifier was able to predict NAC 
response according to molecular subtype, namely that a basal tumor subtype gained most survival 
benefit of NAC (24). In sum, the poor prognosis of MIBC justifies the intense research focused 
on this malignancy, a priority we are now beginning to reap the rewards of, with immunotherapy 
being a promising modality. Recent technological advances appears useful in the challenge of 
selecting the patients who will benefit from these therapies. 
1.2 AN INTRODUCTION TO THE IMMUNE SYSTEM 
The human immune system is a web of intricately interconnected functions with the mutual 
mission to protect the organism from non-self entities of potential harm. To prevent this 
safeguarding from inducing damage to self, a solid regulatory arrangement of tolerance makes up 
a considerable part of this web. Traditionally, the immune system is considered to comprise two 
major arms; the innate arm which is immediate but non-specific and the adaptive arm which is 
specific and may acquire memory. Although this view is simplistic, as these arms to a large degree 
are entwined and inter-dependent, the main principles still hold. The following passages give an 
introduction to these branches using the example of a skin wound contaminated with extracellular 
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bacteria. The concluding sections serves to give an in-depth but concise description of immune 
tolerance. 
1.2.1 The innate and adaptive immune response to a dirty wound 
Upon contracting a skin wound with concomitant infection of extracellular bacteria, the innate 
arm, as a first line of defense, will provide resistance through various mechanisms. For instance, 
antimicrobial peptides will be secreted by tissue-resident innate- and epithelial cells. Membrane 
disruption and bacterial cell lysis may be exerted by the complement system (a set of plasma 
proteins that may carry out effector mechanisms of host defense upon activation). Crucially, 
innate immune cells, such as macrophages, are equipped with pattern recognition receptors 
(PRRs). These PRRs recognize and bind to pathogen-associated molecular patterns (PAMPs) 
such as the bacterial component Flagelin and to damage-associated molecular patterns (DAMPs) 
such as high mobility group box-1 (HMGB1).  
Activation of PRRs may induce a series of events. Typically, in a macrophage, the transcription 
factor nuclear factor-κB (NF-κB) may be activated through its canonical pathway which 
stimulates the production of a plethora of pro inflammatory factors including cytokines and 
chemokines. These factors recruit and activate other innate cells such as neutrophils whose influx 
usually peaks within the first 6 hours of an inflammatory response. Once in the inflamed tissue, 
neutrophils may kill the bacteria through phagocytosis if provided the proper PRR- and 
complement receptor signaling. Other factors that may be secreted as a consequence of the 
activation of this pathway are i) Interleukin (IL)-6 which will stimulate the production of                 
C-reactive protein, an acute phase protein which enhances the activation of the complement 
system, and ii) Tumor necrosis factor-α (TNF-α), a protein with multiple functions, including 
preventing bacteria to enter the bloodstream by triggering blood clotting in the local small vessels, 
occluding them.  
Owing to their superior efficiency as antigen presenting cells (APCs) and their high capacity to 
migrate to T cell zones, dendritic cells (DCs) constitute a critical link between innate and adaptive 
immunity. In the skin, two types of DCs reside; Langerhans cells residing in the epidermis, and 
in the dermis, dermal DCs reside. If we envision that the skin wound in this example is rather 
superficial, LCs will capture the bacterial antigen by means of phagocytic receptors or 
macropinocytosis. Consequently, a class of PRRs called Toll-like receptors (TLRs) are activated 
and their signaling results in a “licensing” of the DC. This licensing involves alteration of the 
DCs’chemokine receptor profile enabling it to leave the skin and enter the lymphatic system 
where they further mature and acquire the ability to present the antigen to the adaptive arm of the 
immune system.  
The AIS consists of T and B cells. In principle, each of these cells has a receptor specific for only 
one particular, cognate, antigen. Although these receptors share many features, the nature of the 
antigens and the mode of recognition differs which reflects the different functions of these two 
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lineages. While the B cell receptor (BCR) may recognize and directly bind antigens of various 
kinds such as lipids, polysaccharides and protein, the T cell receptor (TCR) instead recognizes 
short peptide fragments only from protein-derived antigens presented on a specific MHC pocket 
expressed on the APC. The MHC molecule is a glycoprotein with a pocket or cleft running across 
their outermost surface, in which a variety of peptides can be bound. This requirement of a 
specific peptide-MHC complex, is referred to as MHC restriction as the TCR needs to recognize 
structures both of the peptide antigen and of the MHC molecule to which it is bound, in order for 
the T cell to be activated. Such recognition constitutes the first signal out of three required signals 
for full T cell activation.  
Eventually, the DCs enter the T cell zone of a draining lymph node and if the DCs are exposed to 
additional common microbial constituents (often called “danger signals”) such as unmethylated 
bacterial DNA, they acquire the ability of co-stimulatory activity. The best characterized co-
stimulatory molecules are the B7 molecules which ligate to their cluster of differentiation (CD) 
28 surface receptor on the T cell which constitutes the second signal needed for T cell activation. 
At this stage of activation, the T cell start to proliferate and express the α chain of the IL-2 receptor 
(also known as CD25) which increases IL-2 signaling leading to an amplified clonal expansion 
of this T cell. However, in order to mount an adapted response towards the assaulting pathogen, 
the generated T cell clone must differentiate into one of several functionally distinct T effector 
cell (Teff) subsets. In this example of an extracellular bacterium, the antigen peptide would be 
presented on a MHC class II molecule, the class of MHCs presenting exogenous antigens. There 
are two major T cell populations; those expressing the co-receptor CD8 (i.e. CD8+ T cells) which 
bind to MHC class I or the co-receptor CD4 (i.e. CD4+ T cells) binding to MHC class II. Thus, 
only CD4+ T cells are typically activated upon extracellular bacterial infection. Based on their 
effector functions, CD4+ T cells are, in turn, divided into several subsets. We here consider the 
secretion of IL-4 from the APC that would support polarization towards the CD4+ Th 2 cells, a 
subset primarily involved in promoting humoral immune responses towards extracellular 
pathogens.  
A fraction of the newly formed CD4+ Th2 cells would migrate towards a primary follicle of the 
lymph node – the area where B cells reside. Similarly to DC’s, although with some key 
differences, some B cells would have picked up antigens through their BCR’s and presented the 
processed peptides on their MHC II molecules. Mediated by chemokines such as CCL21 and 
CXCL13, B cells and T cells then co-localize at the junction between the T cell area and the B 
cell follicle where they form a primary focus. Here, the previously Th2, differentiates to a                         
T follicular helper (Tfh) cell and may now, through the expression of CD40 Ligand (CD40-L) 
and IL-21, signal to the B cells to proliferate and differentiate. Remarkably, the Tfh cells will 
only do so, if it has been activated by an antigen closely associated to the antigen recognized and 
presented by the B cell – a mode of immune regulation called “linked recognition”. 
Some activated B cells migrate back into the follicle, accompanied by Tfh cells and form a 
germinal center where they (the B cells) undergo three processes fundamental for effective 
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antibody function; somatic hypermutation, affinity maturation and class switching. These B cells 
differentiate into either memory B cells or plasma cells which will contribute to elimination in 
the later stage of the infection by secreting versatile antibodies that may i) neutralize the bacteria 
ii) facilitate phagocytosis by binding and thereby “marking” the bacteria (opsonization) and iii) 
activate the complement system.  
Once the infection is cleared, all these described “on signals” need to be turned off. How this is 
accomplished, as well as other dimensions of immune regulation, is covered in the following 
passages. However, as a final note, similarly to the B cells, also a subset of the activated antigen-
specific T cells will differentiate into memory cells of different subsets such as CCR7+ central 
memory, CCR7- effector memory and CXCR3+ tissue-resident memory T cells which can rapidly 
be re-activated if we are infected by the same pathogen again. 
1.2.2 Two types of receptors, two types of adaptive immunity 
B cells, together with their antibodies, are the main contributors to our humoral immunity, as they 
largely mediate their effects in fluids such as blood and mucosa, particularly in the extracellular 
space. This niche is possible because the BCR may i) recognize soluble antigens in their native 
form and ii) be secreted as an antibody and exert various effector functions directly on the 
pathogen. In contrast, T cells, because of the MHC-restricted TCR, requires a physical cell-cell 
contact to be activated and subsequently mediate their effects, hence T cells provide cell-mediated 
immunity.  
Albeit these lineage defining differences in how their receptor works, the complex processes in 
which BCRs and TCRs are generated, are much similar. A basic understanding of these 
procedures is useful for the comprehension of immune tolerance, a recurring theme in this thesis. 
So, highly simplified, to recognize the diverse array of antigens an individual may encounter 
during the course of a lifetime, a broader receptor repertoire than could be encoded in the human 
genome, considering its limited size (of roughly 3 billion nucleotides), would be necessary. This 
problem is solved by two main mechanisms: the first is by combinatorial diversity which is the 
random recombination of multiple gene segments scattered across the chromosomes into one 
exon encoding the variable region (V-region) of the BCR or TCR. These V-regions encode the 
antigen binding regions of the heavy- and light-chain for BCR and of the α- and β-chain for the 
TCR. The second mechanism is junctional diversity; an imprecise incorporation of non-encoded 
nucleotides in the joints of these gene segments. Together, these processes form the basis for both 
TCR- and BCR diversity and are enabled through the expression the lymphocyte-specific 
recombination activating genes (RAG 1 and 2). However, the B cell takes advantage of two 
additional sources of diversity. The first is also of combinatorial character and arises from the 
many possible different combinations of heavy- and light-chain V-regions that may pair to form 
the antigen-binding site. Finally, somatic hypermutation, which is the insertion of point mutations 
in the V-regions of the heavy- and light-chain upon antigen encounter to improve the antigen 
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recognition and binding capacity of the antibody, but, coincidentally, the potential of receptor 
diversity also increases. 
1.2.3 Central tolerance 
As discussed previously, the ability of our AIS to recognize and eliminate an extraordinary 
diverse array of outer threats comes with the cost of an increased risk to recognize and evoke 
immune responses against self. Our solution to this challenge, to distinguish between self and 
non-self, is referred to as central and peripheral tolerance. For T cells, central tolerance is 
molded in the thymus, whereas for B cells, this process take place in the bone marrow, 
discussed below. 
1.2.3.1 Receptor editing and clonal deletion of B cells 
B cells are continuously throughout life developed in the bone marrow. The process starts with a 
Common lymphoid progenitor (Clp) differentiating into a pro-B cell. At this stage, the heavy 
chain locus is rearranged and those cells that manage to produce the µ isotype receive a survival 
signal and become pre-B cells. In Pre- B cells, the light chain locus is rearranged followed by 
allelic exclusion which is the process where one of the alleles for both the light-chain and the 
heavy chain loci is “turned off”, ensuring that the B cell will only have one antigen specificity. 
The transition into the state of an “immature B cell” is defined by the pairing of the light chain 
with the heavy chain, resulting in the expression of Immunoglobulin (Ig) M on the cell surface 
(as a surface IgM, or sIgM).  
The immature B cell is tested for autoreactivity through exposure to self antigens. For self-
reactive B cells, depending on how the sIgM interacts with the self antigen, there are four possible 
outcomes. If the sIgM binds self antigen monovalent or with low affinity, the B cell mature 
normally and may be self-reactive, however is considered “clonally ignorant”, as they are unable 
to be activated by their ligand. If the self antigen is able to cross-link sIgMs, the immature B cells 
are rendered unresponsive (anergic) to the antigen and migrate to the periphery, where they 
remain anergic. In the event of binding multivalent self ligands, for example an MHC molecule, 
a process referred to as receptor editing is initiated. In short, RAG expression continues which 
enables secondary rearrangement of the light chain locus and a new chance to generate an 
appropriate sequence that does not cause self reactivity upon expression. If this fails, the B cells 
undergo clonal deletion, in which apoptosis is induced as a means to weed out potentially 
damaging autoreactive cells from the repertoire.  
If receptor editing succeeds, or if there was no self -reactivity in the first place, the immature B 
cells leave the bone marrow and undergo their final maturation steps in the spleen. Notably, most 
of the immature B cells will not survive to reach final maturation due to harsh competition to 
access a spleen follicle which is needed to receive survival signals from a subtype of DCs called 
follicular DCs. However, those that do survive, either differentiate into mature follicular B cells, 
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representing the majority of B cells, or marginal zone B cells, predominantly found in the 
marginal zone of the spleen. 
1.2.3.2 Thymic selection of T cells 
The life of a T cell begins in the thymus and is preceded by the migration of a Clp cell from the 
bone marrow. Once reaching the thymus, the Clp may receive notch signaling from a thymic 
epithelial cell (TEC) which makes it commit to the T cell lineage. Next follows a tightly regulated 
sequence of events which surround the development of the TCR and includes massive 
proliferation but also strikingly extensive cell death.  
The initial phase of differentiation generates cells that bear distinctive markers of the T cell 
lineage but do not express the co-receptors CD4 or CD8, i.e. double-negative (DN) thymocytes. 
These give rise to both α:β and γ:δ T cells, however we here focus on the former subset. The DNs 
migrate through the thymic cortex and sequentially pass through four stages (DN1, DN2, DN3 
and DN4) defined according to the expression of the markers CD44, CD25 and Kit. The main 
events in these developmental stages are related to the rearrangement of the TCR gene loci which 
is initiated at the DN2 stage and continue in DN3 cells. At this stage, a predecessor to the TCR, 
namely the pre-TCR is assembled by the pairing of the β chain with a surrogate pre-TCR α chain 
which trigger thymocyte proliferation and blocks further β chain rearrangement. Those cells that 
fail to produce a successful β chain rearrangement die by apoptosis, making DN3 a first 
checkpoint in T cell development. In the DN4 stage, rapid cell proliferation occurs, and eventually 
both CD4 and CD8 co-receptors are expressed, i.e. double-positive (DP) thymocytes are formed. 
Once the DPs cease to proliferate, their α chain locus begins to rearrange with the subsequent 
formation of a functional α:β TCR complex. At this stage, the harsh selection processes are 
initiated. 
Only 2-5 % of all developed thymocytes survive positive and negative selection, highlighting 
their extensive filter-effect. Although evidence suggests these as quite parallel processes, positive 
selection is still considered to be first initiated. It encompasses survival- and maturation signals 
from cortical TECs to those DPs whose newly formed TCRs manage to engage to a self-
peptide:self MHC complex. The DPs who fail this enterprise have “useless” TCRs 
(approximately 90 % in the mouse thymus), with the subsequent absence of intrinsic survival 
signals and, therefore, die by neglect. The positive selection procedure also coordinates the 
commitment to either the CD4 or CD8 lineage as TCR recognition of self peptide:self MHC II 
results in loss of CD8 expression and vice versa. Upon becoming single-positive (SP), the 
thymocytes express high levels of their TCRs and migrate to the thymic medulla.  
As a direct effect of positive selection, all T cells are self-reactive to a certain degree. In the first 
step towards establishing tolerance to self, a negative selection process ensues in which 
thymocytes exhibiting a TCR which strongly ligates to the self peptide:self MHC complex, are 
induced to die by apoptosis. This process occurs throughout thymocyte development, both in the 
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thymic cortex and in the medulla. Exactly what cells that mediate this death induction in the 
thymic cortex remain unresolved. However, in the medulla, a bone-marrow derived antigen-
presenting cell type known as medullary TECs (mTECs) have been shown to directly induce 
thymocyte negative selection. A key feature of mTECS is their expression of the AIRE 
(autoimmune regulator) gene (25). AIRE triggers the ectopic expression of genes encoding tissue-
specific antigens which, in coordination with thymic DCs, enable a diverse repertoire of self 
antigens to be presented and strongly self-reacting thymocytes to be deleted (25).  
The few thymocytes surviving the selection processes undergo final maturation in the medulla 
which involves changes in the TCR signaling machinery so that binding to the TCR results in 
proliferation as opposed to apoptosis - the default mode of a developing thymocyte. The 
expression of Sphingosine-1-phosphate receptor 1 (S1PR1) marks the final T cell maturation step 
and enables the emigration from the thymus into the bloodstream. 
1.2.4 Peripheral tolerance 
Unfortunately, negative selection does not remove all strongly self-reactive T cells. Other 
mechanisms operating in the periphery are necessary to counteract autoimmunity.  
Regulatory T cells (Tregs), with their capacity to suppress immune responses, represent a pivotal 
such tolerance modality (26). 
1.2.4.1 Regulatory T cells 
Tregs were first identified as a CD4+ T cell subset expressing high amounts of CD25 and capable 
of suppressing autoimmunity in mice, a pioneering work of Sakaguchi et al. in 1995 (2). Since 
then, a broad heterogeneity within the Treg population has been demonstrated. Even though 
“generic Tregs” may not exist, some main characteristics are mutual for the vast majority of the 
to date identified Treg subpopulations; Tregs migrate to inflammatory sites and, by both cell- and 
non-cell contact dependent mechanisms, are able to suppress other immune cells such as APCs 
and T eff cells (26). By these means, Tregs mediate peripheral self tolerance, maintain immune 
homeostasis and protect against autoimmunity. 
The potential therapeutic use of Tregs has been implicated in a broad range of diseases, spanning 
from diabetes to cancer. Ample data support their central role within the tumor-immune interplay, 
however that topic will be revisited in a later section. Instead, here follows a palette of 
physiological-centered Treg facets including their origin(s), main markers, subpopulations, 
epigenetic regulation, plasticity and functionality.   
1.2.4.2 Treg cell development 
Two origins have been described for Tregs; thymic differentiation from immature T cell 
precursors into tTregs, which constitutes the major Treg population, and peripheral induction 
from naïve Teff cells (pTregs). A cardinal feature of tTregs is that, unlike naive Teff cells, they 
differentiate into a functionally mature and stable cell lineage within the thymus. This process is 
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a rather recent addition to the T cell fates - and still a matter of intense investigation. It is clear 
that Treg development involves phenotypically distinct stages with specific transcriptional and 
cytokine requirements. 
Cellular signaling during thymic Treg development  
Several lines of evidence indicate the thymic medulla as the main scenery for tTreg development. 
For instance, tTreg cell generation is dependent on an intact mTEC compartment (27). 
Additionally, tTreg differentiation is promoted by AIRE-dependent antigens presented by 
mTECS but also by B cells (28, 29). The above data is derived from mouse studies, knowledge 
of tTreg development in humans is somewhat limited. However, Watanabe et al. reported that 
epithelial cells of Hassall´s corpuscles, structures (located in the medulla) unique to human 
thymic histology, produce thymic stromal lymphopoietin (TSLP) which promoted thymic DCs 
to induce differentiation of SP CD4+CD25− thymocytes into distinct forkhead box P3+  (FOXP3+) 
Treg subsets (30, 31).  
The transcription factor FOXP3 is a distinctive feature of Tregs that is essential, but not entirely 
vital for Treg development (32, 33). Although FOXP3+ cells have been observed at the more 
immature thymocyte stages (34), diversification to the Treg lineage, is considered to take place 
subsequent to positive selection from CD4+ CD24high SP thymocytes (35-37).  
How and which thymocytes selected to become Tregs is, at least in part, determined by the self-
reactivity of the TCR. More specifically, the consensus has been that those thymocytes that may 
differentiate into Tregs are those with a TCR that binds the self peptide:self MHC stronger than 
would result in differentiation into Teff cells but still with less avidity than would induce negative 
selection (35, 38). This model is supported by studies using TCR transgenic mice combined with 
several knockout strains deficient of molecules downstream of TCR and co-stimulation signaling 
(reviewed in (38)). As a consequence of this selection process, the Treg TCR repertoire is skewed 
toward recognition of self antigens but, reportedly, is as broad as that of Teff cells (36, 39). 
Recent insights have nuanced the view of tTreg development as data indicate that, although 
binding strength is an important factor, the duration of the antigen-TCR binding is what specifies 
the tTreg cell fate (36). Supportive to this “hit-and-run model” is the finding that transient, but 
not continuous, TCR stimulation induces robust FOXP3 expression in CD4 SP T cells (40, 41). 
Moreover, in thymic precursor cells expressing transgenic Treg-derived TCRs, there is a 
pronounced intraclonal competition for further differentiation (42, 43), implying that tTreg 
differentiation is facilitated by ligands present in limiting amounts in the medulla. 
Although, these studies provide solid evidence for the requirement of proper TCR signaling, the 
downstream molecules hypothesized to serve as key regulators of Treg-type gene expression (in 
addition to FOXP3), remain to be identified.  
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Ample data have delineated a two-step process for the thymic generation of Tregs in which TCR 
signaling in conjunction with the intermediate binding-avidity to an antigen is the first step (44). 
This allows transcriptional changes and increases in cell-surface expression of the α-chain of the 
IL-2 receptor (CD25). Signaling by IL-2, via the intrinsic signal transducer and activator of 
transcription 5 (STAT5) leads to induction of FOXP3 expression and represents the second step 
(44, 45). The critical source of thymic IL-2 during Treg development is from other T cells as 
recently demonstrated in mice by selective deletion of IL-2 in T cells, B cells and DCs (46). The 
level of IL-2 was demonstrated to be partly regulated by peripherally activated Tregs recirculating 
to the thymus and sequestering IL-2, thus restricting tTreg development through a negative 
feedback loop (47).  
Epigenetic control during thymic Treg development  
The establishment of a Treg-specific epigenetic pattern could be added as a third prerequisite for 
tTreg development (35). Given the transcription-factor-dependency of this process, an open 
chromatin structure is critical for the binding of these factors to their target sequences. Such 
genome arrangements represent parts of the ever-growing Treg epigenetic landscape. To date, it 
comprises  ̴ 300 Treg-specific demethylated regions (TSDRs) and  ̴ 70 regions comprising a subset 
of enhancers referred to as super-enhancers (SEs) with Treg-specific epigenetic changes. These 
are typically located in the vicinity of Treg signature genes such as Foxp3, Il2ra, and Ctla4, 
rendering a positive epigenetic control of Treg-type genes (37). With regards to Foxp3, five 
conserved regulatory elements within the Foxp3 locus have been discovered: the promoter region 
(48) and the conserved non-coding sequences (CNSs) 0-3 (49-52). 
Recent studies of stage-specific epigenetic changes in the course of tTreg cell development have 
demonstrated the importance of condensed chromatin to be opened and activated in regulatory 
elements such as the CNSs and the Treg-SEs. For example, the chromatin organizer Satb1 was 
found in tTreg precursor DP cells to occupy CNS0 and to assort the chromatin, including histone 
modifications, to a poised state that allows DNA demethylation (49). This Satb1-dependent 
activity was crucial for tTreg development as these cells were absent in Satb1-deficient mice (49). 
Also, these mice exhibited impaired DNA demethylation at the Foxp3 locus, implying that Satb1 
prime Foxp3- Treg precursor for Foxp3 induction.  
Intriguingly, DNA demethylation of Treg signature genes such as Ctla4 and Il2ra is largely 
unaffected by the absence of functional Foxp3. Instead, the DNA demethylation of TSDR’s has 
been reported to be controlled by Ten-eleven translocation (Tet) proteins 2 and Tet3 which work 
redundantly and independent of FOXP3 expression but are dependent on TCR-signaling (53, 54). 
The fate of becoming a Treg appears to be determined before Foxp3 expression with the 
enhancer-landscape framed at the early stage, to pave the way for further imprinting of the Treg 
epigenetic topography including DNA demethylation. This allows subsequent Treg-specific 
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transcription factors, including Foxp3, to be expressed and by selective binding to their target 
sequences, they reinforce the Treg cell lineage commitment. 
The given question is then: what determines the epigenetic topography in the first place? The 
main candidate is TCR activation, since TCR engagement with self ligands is required for the 
demethylation of Treg signature genes as demonstrated in TCR transgenic mice with thymic 
stromal cells expressing the cognate antigen (53). This framework also fits well with previous 
findings of TCR-signaling to dictate the first two steps during Treg development (36, 55). TCR-
guided differentiation has relevance for Tregs beyond their thymic development, which will be 
discussed below, but first, a brief overview of markers for Treg identity and function. 
1.2.4.3 Regulatory T cells markers 
CD25 
The Treg population was first defined as a subpopulation of CD4+ T cells constitutively 
expressing CD25, the high affinity IL-2 receptor α-chain (2). Together with the β- (CD122) and 
γ-chain (CD132), CD25 forms the high-affinity IL-2 receptor (IL-2R). Mice lacking CD25 or 
CD122 suffer from massive systemic autoimmunity, which can be reversed by the adoptive 
transfer of CD4+CD25+ T cells from wild-type mice (56, 57). It is noteworthy that these mice 
contracted autoimmunity rather than infection, because it implies a dominant role of IL-2 to act 
on Tregs and that for Teff cells, IL-2 is somewhat dispensable. 
Indeed, IL-2 signaling is essential for the thymic and extrathymic differentiation, maintenance 
and function of Tregs (44, 58-60). For instance, the central role of IL-2R-signaling-driven 
activation of STAT5 for the suppressor function of Tregs was demonstrated in mice with 
conditional deletion of the Il2ra and Il2rb alleles in combination with induced expression of an 
active form of STAT5 (61). Through this model system, it was demonstrated that an absence of 
STAT5 or IL-2R resulted in severe loss of Treg suppressor function beyond what could be 
attributed to the accompanying decrease in Foxp3 expression.  
Baecher-Allan et al. showed that only the CD25high population possesses suppressive capacity 
whereas the CD25low/intermediate cells do not suppress T cell proliferation (62). However, CD25 is 
generally upregulated in T cells upon activation, limiting its specificity and usefulness as a Treg 
marker. 
Emphasizing the close relation between Tregs and the IL-2R is the markedly lower concentrations 
required to spark the Treg intrinsic IL-2 signaling machinery and downstream gene activation 
compared to Teff cells (63). This feature, together with the abundant expression of the cognate 
receptor, is the basis for the high IL-2 sensitivity of Tregs (64).   
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FOXP3 
Mutations in the FOXP3 gene is associated with the human disease Immune dysregulation, 
Polyendocrinopathy, Enteropathy, X-linked syndrome (IPEX), highlighting the integral role of 
this transcription factor in the Treg population and in maintaining immune homeostasis at large 
(65). FOXP3 (in mice labeled Foxp3) is, in both mice and humans, paramount for Treg 
characteristics with particular importance in orchestrating their suppressive function (26, 32). 
However, precisely how FOXP3 coordinates this suppression is not fully understood.  
Foxp3 appears to possess two modes of transcriptional regulation in Tregs as several mouse-
model studies have demonstrated both positive and negative control of its target genes (66, 67). 
By its positive, or amplifying, impact on Treg signature genes, Foxp3 acts to stabilize the 
characteristic Treg gene expression pattern, rather than to de novo induce the expression of these 
genes. This notion is based on the findings that Foxp3-deficient Tregs can express Treg signature 
genes, albeit at lower levels and that Foxp3 mainly occupies a pre-established epigenetic 
landscape (33, 68). With regards to its negative transcriptional control, this regulatory mode is 
switched on upon Treg activation which results in a global transcriptional repression (69). Taken 
together, it has been proposed that the dichotomous nature of Foxp3 gene regulation provides a 
scheme of how Foxp3 promotes Treg suppressive function, namely by amplifying signature genes 
like CD25 and CTLA-4 while concomitantly repressing genes typically expressed by Teff cells 
upon activation.  
Approximately 5000 and 700 potential target genes for FOXP3 have been identified in humans 
and mice respectively (66, 70). Among these, there is an overrepresentation of genes encoding 
for immunoregulatory cytokines, growth factors and, in particular, for key modulators of T cell 
activation. For example, the protein tyrosine phosphatase 22 (Ptpn22), which mutated forms are 
associated with numerous autoimmune diseases, is upregulated upon TCR activation in Teff cells 
but inhibited in Tregs (67, 71). 
In contrast to mice, human FOXP3 is not exclusively expressed in Tregs as confirmed by its 
transient upregulation in CD4+CD25- T cells upon activation (72). However, in these cells, 
FOXP3 is mainly in the cytoplasm whereas in Tregs, it is predominantly nuclear (73). In 
agreement, there is controversy regarding the in vitro suppressive capacity of cells with transient 
FOXP3 expression (74). Moreover, human FOXP3 expression is not even restricted to the 
lymphocyte lineage as its expression has been demonstrated in non-hematopoietic cells of various 
kinds and in cancer cells of multiple lineages (75).  
Despite its non-specificity, in lack of practical alternatives, FOXP3 is often used as a marker for 
Treg identity. It follows, that data solely based on FOXP3 expression urges careful interpretation, 
especially in an inflammatory setting where T cell activation is to be expected. 
Adding to the heterogeneity of the human Treg landscape, our species express two main isoforms 
of FOXP3 at similar levels; the full-length protein (FOXP3fl) and the FOXP3∆2, which lacks 
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exon 2 (76). A key functional distinction is that the exon 2 domain is necessary for the interaction 
with the Th17 master transcription factor RAR-related orphan receptor γ (ROR γ) and ROR α. 
Still, the downstream functional relevance of this, and alternative FOXP3 splicing in general, 
awaits further investigation (77). 
Progresses within the field of immunometabolomics have added another layer to the regulation 
of FOXP3 expression. For instance, elevated glycolysis is associated with decreased Treg 
functional stability, in part due to suppression of FOXP3 expression mediated by the metabolic 
regulator mTOR (78). In contrast, the metabolic Hypoxia-inducible factor 1-alpha (HIF-1α) 
pathway has been reported to drive FOXP3 expression, which has been suggested as a mechanism 
for Treg accumulation in the tumor microenvironment (TME), since this pathway is overactive 
in many tumors (79).  
CD127 
The expression of low levels of the IL-7 receptor α-chain (CD127) inversely correlates to FOXP3 
expression and suppressive capacity in human CD4+ T cells (80). Hence, CD127 is considered a 
useful complementary Treg surface marker. However, its complementary usage should be 
stressed since FOXP3+ cells are only enriched to the level of  ̴̴ 40 % of the CD127low population 
(81). Also, CD127 is transiently downregulated in Teff cells early in the course of activation (82). 
Nevertheless, in a workshop where experts in the Treg field participated and systematically 
evaluated various Treg markers in both the cancer- and physiological setting, CD127 was 
validated as a useful marker in both these contexts and suggested to be included in a standardized 
Treg flow cytometry panel (83). This proposal is in line with other findings of the 
CD4+CD25+CD127lo population to enable both improved yield and purity of FOXP3+ cells 
compared to the CD4+ CD127 lo population (80).  
CTLA-4 
The expression of cytotoxic T lymphocyte antigen 4 (CTLA-4) peaks within 48h of activation on 
most resting Teff cells and is only constitutively expressed by the Treg subset (84). In the resting 
state of Tregs, CTLA-4 is mainly localized to intracellular vesicles which upon T cell activation 
fuse with the cell membrane to be exposed on the cell surface, preferably adjacent to the TCR 
(85). CTLA-4 is a key-molecule for Treg suppressive function and activated, suppressive (human) 
CD4+CD25+ Tregs harbor higher CTLA-4 expression than its non-activated counterparts (86). 
On this basis, CTLA-4  is considered a valid Treg effector marker (26). The mechanistic basis for 
CTLA-4 function is described below in the section designated for Treg effector mechanisms. 
1.2.4.4 Functional Treg subsets 
There is a vast phenotypical and functional heterogeneity within the Treg population, reflecting 
the diverse environments and target cells that they regulate. Several markers, and different 
combinations of these markers, have been suggested to further delineate functionally distinct Treg 
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subsets (reviewed in (26, 87)). In this endeavor, assessing quantitative shifts in expression of these 
proteins is preferable to the simple qualitative approach, since Treg-intrinsic molecules linked 
with immune suppression in general are upregulated from the steady state, rather than expressed 
de novo (87).  
Among the earlier markers to be identified for Treg subpopulation delineation, were the naïve 
and memory T cell markers, CD45RA and CD45RO respectively (88). Upon antigenic 
stimulation, the naïve CD45RA+CD45RO-FOXP3+ population converts to CD45RA-
CD45RO+FOXP3+ cells. By quantifying the degree of FOXP3 expression, the CD45RA-
CD45RO+FOXP3+ populations can be further dissected into FOXP3hiCD45RA-CD45RO+ cells, 
referred to as effector Tregs, which are terminally differentiated, highly suppressive and 
functionally stable, and a FOXP3loCD45RA-CD45RO+ subset, less prone to exert suppression 
and with the capacity to secrete pro-inflammatory cytokines (88). Still further, distinct functional 
subsets within the FOXP3hiCD45RA- CD45RO+ population have been identified. For instance, 
the subpopulation with high ectonucleotidase CD39 expression present stronger stability and 
function under inflammatory conditions compared to their CD39low counterparts (89). 
Naïve or resting Tregs do not express the MHC-II molecule HLA-DR but upon activation they 
do and then remains HLA-DR+. In consistency, HLA-DR+CD4+FOXP3high cells have been 
proposed to represent a terminal effector subpopulation of more highly and rapidly suppressive 
Tregs then their HLA-DR- counterparts (90). These qualities grant HLA-DR suitable as a Treg 
activation and memory marker. In contrast, Teff cells only transiently express HLA-DR upon 
activation. 
1.2.4.5 Generation and education of Tregs in the periphery   
The generation of pTregs is fringed with even more uncertainties than that of tTreg cells. This is 
in part due to a lack of a marker or method to distinguish pTregs from tTregs wherefore the exact 
numeral and functional contribution of the pTreg population remains in question. The 
transcription factor Helios or the membrane co-receptor Neuropilin 1 (Nrp1) have been suggested 
to be exclusively expressed by tTreg cells, but consensus has not yet been reached on this matter 
(91, 92).  
Aside from the difficulty to distinguish them, the existence of pTregs and the molecular 
mechanisms by which they are developed are well defined. Briefly, the conversion of Teff cells 
to pTregs in vivo is favored by long-term exposure to sub-immunogenic doses of non-self antigen 
such as food antigens presented by mucosal tissue-resident DCs, accompanied with Transforming 
Growth Factor β (TGF-β), retinoic acids and short chain fatty acids often produced in such 
immunosuppressive environments (93). For example, gut-associated lymphoid tissue-residing 
CD103+ DCs were demonstrated to produce TGF-β and retinoic acid (94).  
pTreg cell differentiation is also boosted by metabolites of the microbiota, such as butyrate or 
propionate and natural antigens from commensal bacteria readily induce pTregs in the colon (95, 
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96). The central role of pTregs in mucosal tolerance was highlighted by the finding that depletion 
of these cells caused dysregulated immune responses both in the gastrointestinal tract and airway 
(97). Their relevance for immune regulation is also manifested by the finding that the in vitro 
suppressive capacity of these cells is equal to that of tTregs (98).  
1.2.4.6 Epigenetic maintenance of Treg stability 
One definition of Treg stability is the maintenance of sustained FOXP3 expression, suppressive 
capacity and lack of effector functions (99). A central mechanism underlying this stability is the 
epigenetic control of the Treg-specific gene network.  
Hill et al. demonstrated elegantly the critical role of the TSDRs and the insufficiency of FOXP3 
to alone maintain the Treg gene signature (100). They found that TCR stimulation of Teff cells 
conferring a retroviral ectopic expression of Foxp3, represses IL-2 and interferon γ (IFN γ), which 
do not possess TSDR, but fails to upregulate TSDR-dependent genes such as Ikaros Family Zinc 
Finger (IKZF) 2 and IKZF4. 
The regulatory element CNS2 located within the FOXP3 locus contains CpG islands which are 
highly demethylated only in functional Treg cells. This methylation pattern is considered to be a 
definitive marker of commitment to the Treg cell lineage (51) and can distinguish a committed 
Treg from a Teff cell transiently expressing FOXP3 both in human peripheral blood and solid 
tumor tissue (35, 101). In diligent interrogations, Rudensky et al. introduced systemic deletion of 
each three CNSs (at the time, CNS1-3 were known) and demonstrated deletion of CNS2 to affect 
the stability of Foxp3 expression during proliferation, pointing out this regions’ importance for 
the heritable maintenance of the active state of the Foxp3 locus and, therefore, for Treg lineage 
stability (60). 
Interestingly, variations within CNS2 methylation patterns (10%–60%) have been reported for 
tumor-infiltrating Tregs (TI-Tregs) (99). Moreover, in vitro TGF-β induced Tregs (iTregs) 
display only a partial demethylation of the CNS2 region (53). In contrast, pTregs exhibit complete 
demethylation of the CNS2 and stable expression of Foxp3 (102). Hence, methylation status of 
CNS2 is a useful marker to distinguish committed Tregs (tTregs & pTregs) from transiently 
FOXP3 expressing Teff cells and iTregs.  
We previously showed that hypomethylation at the CpG position -77 of this promoter represents 
a Treg-specific methylation status (48). Indeed, the transcriptional activity of the FOXP3 
promoter also contributes to the lineage-specific expression of FOXP3, albeit to a lesser extent 
than the CNSs.  
In sum, the Treg-specific epigenetic landscape, installed during Treg development (described 
above) and inherited through cell divisions, is critical for maintaining long-term Treg lineage 
stability. In this regard, demethylation at regulatory elements within the FOXP3 locus appears to 
be of particular importance. 
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1.2.4.7 Treg plasticity 
Is it possible for this rigorously regulated and highly differentiated cell population to be 
reprogrammed into a Teff cell? Considering the therapeutic applications that use or modulate 
Tregs to treat autoimmune diseases, allergies, graft rejection and tumors, the issue of Treg 
stability/plasticity is of considerable practical importance. Yet, the topic is ambiguous to unpack, 
not the least because of the mixed use of nomenclature with regards to lineage and functional 
plasticity in the literature. In the following passages Treg lineage plasticity refers to Treg loss of 
one or several of the following traits: sustained FOXP3 expression, suppressive capacity or lack 
of effector functions. In contrast, functional plasticity refers to the capacity to adapt key features 
to the surrounding environment.  
The issue of Treg lineage plasticity is contentious. Briefly, several Foxp3 lineage-mapping studies 
reported a small population (1–5%) of Tregs that downregulated Foxp3 in response to certain 
lymphopenic and inflammatory cues, suggesting that Tregs can turn into exTregs. These exTregs 
exhibit an increased CNS2 methylation compared to its stable Treg counterpart and secretes IFNγ 
(103). Also, in mouse models of cancer, small populations of exTregs have been observed (99). 
However, these studies have endured skepticism, some regarding exTregs as a methodological 
artifact. In humans, Tregs expressing IL-17 (and IFNγ in some cases) have been reported for 
several inflammatory diseases including psoriasis, inflammatory bowel disease and rheumatoid 
arthritis (104). The maintenance of the suppressive function in these cells was context-dependent. 
Taken together, although Treg lineage plasticity remains controversial, published reports suggest 
that under extreme circumstances, such as strong inflammatory conditions or, on the other 
extreme, lymphopenic settings, Tregs may lose FOXP3 expression and their suppressive 
properties.  
The capacity to respond to stimuli is a basic criterion for life. The capacity of a cell to respond to 
environmental cues and self-adapt, may be viewed as an expansion of that notion. Through this 
perspective, it is easy to conceive that Tregs adapt key features, including their suppressive 
functions and migratory capacity, to the context they are in. For instance, in response to certain 
extracellular stimuli, naive Tregs can express Tbet or increase IRF4 or STAT3 activity, which are 
required for Th1, Th2 and Th17 cell formation, respectively (105-107). The specialized 
regulatory program determined by each of these transcription factors inflicts a unique gene 
expression pattern of the Tregs while maintaining expression of core molecular signatures such 
as Foxp3, CD25 and CTLA-4 expression (37). In a recent report, another such Treg specialization 
was described, namely that Tregs resident in the follicles of chimeric mice spleens (termed 
“follicular Tregs”) uniquely expressed the transcription factor Bcl-6, similar to follicular helper 
T cells (108). Bcl-6-dependent CXCR5 expression recruited the follicular Tregs to the germinal 
center, where they suppressed follicular helper T cells and B cell responses (108, 109).  
Specialized Treg populations are also found in non-lymphoid tissues. A well-studied example is 
visceral adipose tissue (VAT), where Tregs express high levels of PPARγ, a key adipocyte lineage 
 28 
transcription factor (110). In these VAT-Tregs Foxp3 and PPARγ, together mold a distinct 
expression pattern, orchestrating the phenotype and function in this tissue-localized Treg 
subpopulation (110).  
A recent advance in our understanding of the molecular basis for how Tregs adapt to their 
surroundings is the finding that TCR signal intensity shapes activated Treg programs (111), which 
conforms to the concept of TCR-guidance during Treg development in the thymus.  
1.2.4.8 Treg functionality  
Recognition of its cognate (self ) antigen, paired with co-stimulation, is required for Tregs to exert 
suppression (112). However, once activated, the suppressor function of Tregs is non-specific and 
may, via humoral and cell-cell contact mechanisms, target various cell types such as Teff cells, 
natural killer (NK) cells, B cells, DCs and macrophages, as summarized in Figure 1 (113, 114). 
The contact-dependent mechanisms include surface expression of inhibitory molecules such as 
CTLA-4, lymphocyte-activation gene 3 (LAG-3), CD39, CD73 and the T cell immunoreceptor 
with Ig and ITIM domains (TIGIT) whereas the secretion of soluble inhibitory factors such as 
TGF-β, IL-10, Granzymes, Perforin and IL-35 represent contact-independent mechanisms. One 
additional principally different mechanism deserves to be mentioned, namely “out-competition”, 
exemplified by Treg aggregate formation around DC’s and thereby limiting APC access for Teff 
cells. The paracrine IL-2 loop is a similar example, i.e. IL-2 production by Teff cells and 
consumption by Tregs through extensive CD25 expression (115, 116). All these mechanisms 
should be viewed as complimentary modalities, utilized by Treg populations in varying extent 
depending on the contextual setting. The effector mechanisms particularly implied in the cancer 
setting are addressed in a later section.  
CTLA-4 is key for Treg suppressive function and is constitutively expressed by activated and 
memory Tregs (88). The binding of CTLA-4 on Tregs to its ligands B7-1 (CD80) and B7-2 
(CD86) on an APC, activates Tregs to exert suppression. This notion is supported by the 
observation that blockage of this interaction leads to the failure in Treg activation and suppression 
(112). In contrast, CTLA-4 on Teff cells competes with the co-stimulatory molecule CD28 at the 
immune synapse for the binding of their mutual ligands (CD80 and CD86) which provides 
intrinsic inhibition by disrupting the B7–CD28 axis (reviewed in (17)). As an extension of this 
mechanism, Tregs may downregulate both CD80 and CD86 on DCs in an extrinsic manner where 
CTLA-4 (expressed on the Treg), reportedly, binds to such APC-ligands by transendocytosis, 
targeting them for lysosomal degradation (116, 117).  
An additional extrinsic mechanism of CTLA-4 mediated Treg regulation is by reverse receptor 
signaling to DCs resulting in upregulation of indoleamine 2,3-dioxygenase (IDO) in these cells 
(118). IDO catalyzes the degradation of the, for Teff cells, essential amino acid Tryptophan. Both 
the depletion of Tryptophan and the generated metabolites are suppressive for Teff cells. 
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Theoretically, such cell extrinsic mechanisms could also be exerted by Teff cells expressing 
CTLA-4, a subject that remains elusive.  
 
Figure 1: Treg effector mechanisms. Tregs suppress immune responses by using diverse 
mechanism of suppression including: i) the secretion of inhibitory cytokines such as TGF-β, IL-
10 and IL-35 capable of inhibiting Teff cells and DCs, ii) the secretion of cytotoxic agents such 
as granzymes/perforin and iii) the expression of inhibitory cell surface molecules including 
CTLA-4 which restrain antigen presenting cells and Teff cells by e.g. increasing IDO activity in 
DC’s. The high expression of the high-affinity subunit of the IL2 receptor CD25 diminishes IL-
2 levels. CD39/CD73 expression results in elevated pericellular adenosine levels with 
downstream suppressive effects through the A2A adenosine receptor. Figure courtesy of  
Malin Winerdal. 
As a molecule with such immune inhibitory features, the therapeutic potential of blocking   
CTLA-4 and thereby releasing an immunological break has been exploited for various cancers to 
reinforce the patient´s anti-tumor immune response. Blocking antibodies such as Ipilimumab has 
been in use since 2000, yet the mechanistic basis for their effect is not fully understood, discussed 
further in a later section (4).  
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The next wave of co-inhibitory receptor targets being explored in clinical trials includes Lag-3, 
and TIGIT. These belong to the same class of receptors as CTLA-4, but exhibit unique functions. 
Lag-3 is a homologue to the TCR co-receptor CD4 and can suppress DC maturation by interacting 
with MHC II molecules on these cells (119). TIGIT is a direct target gene of FOXP3 and 
engagement of TIGIT on Tregs leads to an upregulation of the suppressive mediator Fgl2, which 
confers superior suppressive function to TIGIT+ Tregs such as selective suppression of Th1 and 
Th17 cell responses, which are dominant in driving autoimmune inflammation (120).  
The ectoenzyme CD39 exercise Treg effector functions and induce a local anti-inflammatory 
environment by catalyzing the first and rate-limiting step in the degradation of extracellular ATP, 
to adenosine (121). CD39 is only constitutively expressed on activated Tregs whereas CD73, 
which catalyze the second reaction, is expressed on both Tregs and other immune cells. Local 
adenosine production limits T cell immune responses primarily through engagement of the  
G-protein coupled adenosine A2A receptor which, in turn, leads to increased cAMP levels in the 
target cells (122). Tregs have also been described to suppress responder cells by directly 
transferring cAMP through gap junctions. As an intracellular second messenger, cAMP may 
trigger a plethora of signaling pathways including the activation of Proteine Kinase A that, via its 
action on Protein Tyrosine Kinase, initiates downregulation of TCR signaling (123).  
1.3 TUMOR IMMUNITY 
The idea that the immune system protects the body against tumor development by recognizing 
and eliminating malignantly transformed cells was formulated in 1957 by Sir Macfarlane Burnet 
in "The Concept of Immunosurveillance" (124). At the time, the experimental approach was to 
excise a tumor from an animal and show that, in many cases, the animals could reject a second 
injection of the same tumor cells. These were the first results to imply the existence of 
immunosurveillance and tumor immunity. Today, this notion has become tough to question 
considering the clinical breakthrough for antibodies releasing the negative regulators of immune 
activation (checkpoint inhibitors), a treatment with unprecedented rates of long-lasting tumor 
responses in patients with various cancers (4). 
A crucial consequence of recognizing the capacity of the immune system to eliminate tumors is 
that all tumors that de facto arise in immunocompetent organisms have been selected to evade the 
host’s immune system. Bearing this in mind, the following chapter discusses some of the key 
concepts of tumor immunity, with a special focus on Tregs.   
1.3.1 Tumor immunogenicity  
Tumor immunogenicity refers to properties of the tumor enabling the host to evoke an anti-tumor 
immune response. In principle, the immunogenicity of a tumor relies on the presence of a tumor 
antigen (antigenicity) combined with a “damage signal” (adjuvanticity) (125). With regards to 
antigenicity, tumor antigens may be divided into three broad categories: Tumor associated 
antigens (TAAs), cancer-germline/cancer testis antigens (CTAs) and tumor-specific antigens 
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(TSAs) (reviewed in (126)). Simplified, this division is based on how tumor-specific these 
antigens are; TAAs being least specific as they derive from proteins encoded for in the normal 
genome and hence occur in normal cells but are aberrantly expressed in certain cancers, whereas 
CTAs are intermediately specific as they normally are only expressed in germ cells (testis and 
ovary) and trophoblast tissues but are frequent in certain cancer cells. Finally, TSAs are uniquely 
expressed in tumor cells and may derive from oncoviral proteins or mutations that, when 
translated, give rise to abnormal proteins bearing neoantigens. Because neoantigens are regarded 
as altered self, they are not presented in the thymus and thus not subjected to central tolerance, 
therefore they represent attractive targets for anti-cancer T cell therapies.  
Antigenicity is required but not sufficient to evoke an adaptive immune response. In fact, an 
elevated availability of antigens in the absence of appropriate immunostimulatory signals has 
tolerogenic rather than activating effects (125). In the context of tumor immunogenicity, such 
stimulatory signals are mediated by DAMPs released by (or exposed on the surface of) stressed 
or dying cancer cells. DAMPs alert the host of “danger” by binding to PRRs and thereby, in the 
presence of an antigen, renders the tumor immunogenic, enabling the initiation of an adaptive 
anti-tumor immune response (127). For instance, the release of HMGB1 from apoptotic tumor 
cells enhances DC-mediated antigen presentation via TLR4 signaling (128). The requirements of 
both antigenicity and adjuvanticity for a tumor to be immunogenic have implications for how a 
patient responds to chemotherapy, discussed in a later section.  
Acknowledging that certain tumors may be immunogenic poses critical questions: why does the 
immune system so often fail to eliminate immunogenic tumors? Is it because of host- or tumor 
factors, or a combination thereof? These issues can, at least partly, be understood through the 
concept of “cancer immunoediting”. 
1.3.2 Cancer immunoediting 
Cancer immunoediting comprises three phases of immune system–tumor interactions during the 
course of tumor development, namely elimination, equilibrium and escape (129). Compelling 
evidence for this concept was provided by the demonstration of tumors developed in 
immunodeficient mice to be highly immunogenic and, in contrast, tumors from 
immunocompetent mice to display reduced immunogenicity (130). Of note, in some cases, cancer 
cells may directly, without passing through an earlier phase, enter into either the equilibrium or 
escape phases. 
1.3.2.1 Elimination & Equilibrium 
The elimination phase is to a large extent a rephrase of tumor immunosurveillance, where 
developing tumors and premalignant cells are recognized and eliminated by the immune system 
before they become clinically apparent. Key components in this phase include molecules and 
cells of both the innate- and adaptive immune system. For example, in the mouse, type I IFNs 
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enhance tumor antigen cross-presentation activity of DCs (131) and promotes induction of CD4+ 
Th1 cells and CD8+ cytotoxic T cells (132). 
Rare cancer cell variants may survive the elimination phase and enter the Equilibrium phase, 
better described as a bilateral Darwinian selection process between the immune system and the 
tumor. In this process, the overall tumor expansion is constrained by immune-mediated tumor 
cell killing, still there is no net tumor cell elimination. Instead, both parties phenotypes are edited 
but the inherent genetic instability of the tumor eventually favors the emergence of tumoral clones 
which are not recognizable and escape the immune system (129). The equilibrium phase was 
evidenced for instance by data of immunocompetent mice injected with a low-dose carcinogen, 
to harbor occult cancer cells for greater than 200 d (133). However, if these mice were depleted 
of T cells and IFNγ on day 200, tumors rapidly appeared at the site of injection.  
Anti-cancer responses by effector CD8+ and CD4+ T cells  
The strongest evidence of tumor immunity in humans comes from the plentiful reports of the 
quantity, quality and spatial distribution of tumor-infiltrating lymphocytes (TILs) to correlate 
with patient outcome (reviewed in (134)). Indeed, we have previously demonstrated tumor-
infiltration of T cells to correlate positively to survival in UBC (135). TILs may correlate 
positively or negatively to prognosis depending on the particular TIL subset. As a rule, high 
densities of memory T cells with a Th1 phenotype and a pronounced CD8+ compartment, 
correlate with favorable prognosis. A description of the behavior of CD8+ and CD4+ T effs and 
their impact on tumor immunity, here envisioned to occur during the elimination and equilibrium 
phases, follows below. 
 
Given the wealth of preclinical and clinical data of both these cell types to promote tumor 
immunity, the underlying cellular mechanism for how CD8+ and CD4+ T cells eliminate tumors, 
is poorer than one would expect. The anti-tumor properties of activated CD4+ Teff cells are 
limited by MHC restriction because most tumors do not express MHC class II, preventing CD4+ 
T cells to recognize them as target cells. In naïve CD8+ T cells, due to most tumor antigens being 
exogenous, MHC restriction gives another limitation, namely a dependency on cross-priming, a 
process in which APCs present exogenous antigens on MHC I molecules, otherwise only 
presenting endogenous antigens.  
Once activated, by virtue of their ability to recognize and directly suppress, or even kill, their 
target cells, CD8+ cytotoxic T cells are considered a potent force in the anti-tumor immune 
response. When a CD8+ cytotoxic T cells recognizes a tumor antigen-MHC I complex expressed 
on the tumor cell, it forms an immunological synapse (IS). The IS is stabilized by the binding of 
lymphocyte function-associated antigen-1 (LFA-1), expressed on the CTL, to the ICAM-1, 
expressed on the surface of the target cell. This enables the CD8+ cytotoxic T cell to employ a 
key mechanism by which they kill the target cell, namely the release of perforin and granzymes, 
where granzyme B is a prominent sort. These cytotoxic molecules are stored in lytic granules. 
Once the IS is formed, these granules moves along with microtubule organizing centers, which 
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redistribute themselves towards the IS. A sequence of events follows after which the cytotoxic 
constituents are degranulated from the CD8+ T cells. Perforin molecules then bind to the surface 
of the target cell to form pores through which granzymes diffuse into, reaches the cytosol and 
induces apoptosis.  
The critical role of this pathway in tumor immunity is underscored by findings of mutations in 
the PRF1 gene to increase the susceptibility to develop various human cancers (136). In 
congruency, we have previously reported on tumor-induced downregulation of perforin in TME 
resident CD8+ T cells in patients with UBC (137).  
The potential antitumor protective role of CD4+ T effs, has been less obvious compared to CD8+ 
T cells. Perhaps because most tumors do not express MHC class II. Nevertheless, the exceptions 
are notable, as tumoral HLA-DR expression correlates to a favorable prognosis (138), and 
emerging evidence suggest a substantial contribution of certain CD4+ T cell subsets to the anti-
tumor immune response. The Th1 oriented subset, which origin from naïve CD4+ T cells 
previously subjected to priming in the context of e.g. IL-12 and induction of the transcription 
factor T-bet, is the given example. Typically, these cells secrete their signature cytokines IFN-γ 
and TNFα in response to intracellular pathogens, which activates macrophages and enhances 
CD8+ T cell responses. 
These characteristic Th1 effects also have relevance in the cancer setting. Remarkably, IFN-γ and 
TNFα may drive cancer cells into a state of senescence and permanent growth arrest in mice, 
mediated through the p16Ink4a/Rb pathway (139). Moreover, these cytokines may enhance tumor 
immunity by upregulating the expression of MHC I and MHC II molecules on both tumor cells 
and tumor-resident APCs. Also, Th1 cytokines contribute to the maturation and licensing of DCs 
(140). Moreover, CD4+ Th1 cells help in recruiting innate cells including natural killer (NK) cells, 
type I macrophages (addressed below) and eosinophils to tumor sites, where they can act in 
concert toward tumor elimination (141).  
A central feature of CD4+ T cells is their ability to recruit CD8+ T cells and both induce and 
sustain functional memory CD8+ T cell responses. Indeed, CD4+ T cells have been demonstrated 
to promote tumor eradication through this feature, mediated partly by their ability to secrete IL-2 
(142). Consistently, there are successful examples of the clinical use of CD4+ Teff cells in cancer 
immunotherapies, including ACT, as we have previously reported for in UBC (143) and others 
for melanoma (144). Taken together, CD4+ Teff cells, particularly the Th1 subset, reinforce 
multiple distinct aspects of the anti-tumor immune response, suggesting an underestimated 
potential of this cell compartment for the use in cancer immunotherapies. 
Because of a highly unstable genome, of probabilistic reasons, the equilibrium ensues to an 
escape phase, which unfortunately is the dominating phase at the time of diagnosis. At this stage, 
an immunosuppressive TME has been established which empowers the cancer cells to rapid 
growth.  
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1.3.2.2 Tumor Immune escape 
The capacity of a tumor cell to escape immune destruction is considered a “hallmark of cancer”(6) 
and occur through mechanisms involving tumor cell-intrinsic factors and changes in the 
microenvironment, where diverse cell types, including immune cells, reside. These mechanisms 
can be divided into three major categories: i) lack of recognition, ii) lack of susceptibility and iii) 
induction of immune suppression, discussed below, with focus on the latter category. 
Lack of recognition & susceptibility 
Multiple means of the cancer cell to disrupt its antigen presentation have been identified. 
Mutations in the ß2-microglobulin genes are common, resulting in defect, and in case of 
deleterious mutations, a complete loss of MHC I expression (145). Other examples are mutations 
or downregulations in the Transporter associated with Antigen Processing protein (TAP) 1 and 
TAP 2, preventing normal processing and presentation of tumor antigens (146). 
Given that antigenicity is a prerequisite for a tumor to be immunogenic, it would be reasonable 
to presume that disruption of antigen presentation represent a predominant escape mechanism. 
However, tumors lacking T cell infiltration appear to possess similar levels of antigens as their 
highly T cell infiltrated counterparts (147, 148). Similarly, within the same patient, metastatic 
tumor lesions may differ drastically with regards to T cell infiltration (149) and even between 
sublocations of a single tumor lesion, the T cell contexture may differ (as described in the 
appended “paper I” (150)). Together, these observations suggest that dominant suppressive 
mechanisms, through molecular alterations in tumor cell-intrinsic oncogenic pathways amount to 
a significant category of immune escape mechanisms. Indeed, several such pathways with a 
known capability to mediate carcinogenesis or cancer progression from within the tumor cells 
themselves have been found to also mediate immune evasion (reviewed in (151)).  
Resistance to cell death is another hallmark of the cancer cell (6) with apoptotic pathways 
frequently being turned-off or counter regulated, including downregulation of the cell death 
receptor Fas (6). Tumors may also directly counteract cytotoxicity, exemplified by a recent 
finding of actin-remodeling in breast cancer cells to reduce susceptibility to NK cell-mediated 
killing by Granzyme B secretion (152). 
Induction of immune suppression  – by inhibitory molecules 
Tumors may operate on several levels to induce immune suppression. On the molecular level, 
there is a myriad of suppressive molecules synthesized by the tumor itself including i) IDO, which 
immunosuppressive effects are mediated by Tryptophan degradation, (as discussed above in the 
context of Treg effector mechanisms) (153), ii) suppressive cytokines like TGF-β (reviewed in 
(154)) and iii) suppressive chemokines. An example of the latter is tumoral secretion of the 
chemokine Cxcl1 which results in the suppression of T cell trafficking into the tumor as 
demonstrated in a recent study (155). The elevated tumor expression of Cxcl1 was found to be 
due to an epigenetically altered and more accessible promoter region in these cancer cells. Such 
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alterations were not observed in corresponding tumors but with a pronounced T cell infiltration 
(155). Notably, this was true even when comparing two tumors with differential T cell abundance 
but carried by the same mouse, emphasizing this mechanism as a tumor- rather than a host factor.  
Induction of immune suppression – by hijacking immune checkpoints 
Another level of induced immune suppression is the hijacking of immune checkpoints. Within 24 
hours of activation, T cells express Programmed cell Death protein-1 (PD-1), a transmembrane 
inhibitory receptor (156). The binding of its dominant ligand, PD-L1, and the subsequent 
activation of the PD-1 intrinsic pathway down-modulates Teff cell effector functions through 
dephosphorylation of signaling molecules downstream of the TCR (156). In addition, continuous 
PD-1 signaling in T cells ultimately induces an epigenetic program of T cell exhaustion (157). 
Since PD-L1 is broadly upregulated in tissue cells at sites of inflammation, the negative feedback 
provided by the PD-1/PD-L1 axis, is considered a key immune checkpoint, protecting against 
autoimmunity and tissue damage, similarly to the CTLA-4/CD80/86 axis (156).  
The tumoral hijacking of the PD-1/PD-L1 axis, refers to the altered expression of PD-L1 observed 
in numerous cancer types, which inhibits the antitumor T cell response (156, 158). The host-
protective effect of the checkpoint instead becomes tumor promoting. In agreement, therapeutic 
PD-1/PD-L1 blockage has proven an efficient immunotherapy in several cancers, similarly to the 
blockade by Ipilumimab on CTLA-4 (4). Based on the differential kinetics of CTLA-4 and PD-1 
expression, CTLA-4 blockage is considered to act at the priming step, mainly in lymph nodes, 
while PD-1 blockage is thought to release the negative regulation of already antigen-primed  
T cells within the TME (156).  
The response rates for PD-1/PD-L1 blockage varies greatly (15-90 %) across cancer types (4). 
For urothelial cancers this figure is 15-25 % (15), thus finding biomarkers for response is a 
research priority. PD-L1 expression alone has not proven reliable for this assignment. The current 
understanding is that a preexisting antitumor T cell response is necessary but not always sufficient 
for a significant therapeutic response (4). Because tumoral PD-L1 is most frequently expressed 
reactively upon a T cell attack, it might be viewed as a surrogate for an evoked T cell response 
(4, 159). In this setting, co-localization of CD8+ T cells, PD-L1 and PD-1, at the invasive front 
(IF) of the tumor is associated with response to PD-1 blockade (159).  
The expression of PD-1 by Teff cells have been suggested to denote exhaustion. This notion is 
based on the observation that when Teff cells are repetitively stimulated by antigen (as with 
cancer), the level of PD-1 expression remains high and the continuous PD-1 signaling in these 
Teff cells eventually induces an epigenetic scheme of T cell exhaustion (157). However, it is 
important to keep in mind that this does not mean that PD-1 expression per se stands for 
exhaustion. In fact, since PD-1 expression can be due to recent or ongoing T cell activation, in 
certain context, its expression may rather mark the cells with the best capacity to become activated 
and to evoke an anti-tumor response. Furthermore, exhausted CD8+ T cells in the setting of 
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chronic infection, are capable of re-expansion and to exert protection upon transfer to naïve mice 
upon re-challenge with acute infection (160). These notions call for caution when interpreting 
data on PD-1 expression. 
Induction of immune suppression – by recruiting Tregs 
A third level of induced immune suppression is the exploitation of suppressive cells, including 
Tregs, by the tumor. This passage will focus on the behavior of Tregs in the TME.  
An increased frequency of Tregs have been observed in peripheral blood, tumor tissue and tumor 
draining lymph nodes in many human cancers (161). Such Treg accumulation is often associated 
with poor prognosis (162). Experimentally, the involvement of Tregs in tumor immunity was first 
demonstrated by Shimizu et al who found that CD25 depleted mice exhibited tumor rejection and 
retardation of tumor growth (163). Since then, the negative impact of Tregs in the cancer setting 
has been well corroborated, both epidemiologically and mechanistically, albeit experimental data 
is mostly derived from mouse studies.  
Given the relative autoreactivity of Treg TCRs, Tregs have been proposed to exhibit an enhanced 
ability to recognize not only self-antigens but also tumor antigens, since these often are “quasi-
self” (162). This notion, together with the observation that Tregs in general are in a more antigen-
primed state (as illustrated by higher expression levels of T-cell accessory molecules such as 
LFA-1), suggests that Tregs are more prone to be activated by a given tumor antigen compared 
to Teff cells (116, 162). Indeed, Treg clones established from human melanoma recognize TAAs 
such as gp100, TRP1, and survivin (164). It is not clear if these antigens are exclusively 
recognized by Tregs or could also be recognized by Teff cells.  
Considering that the Treg configuration favors immunosuppression over an anti-tumor attack by 
Teff cells, it is easy to conceive that tumors apply active means to recruit and exploit Treg 
functions in its microenvironment. For instance, tumor cells and TME-resident macrophages 
produce the chemokine CCL22, which mediates trafficking of CCR4 expressing effector Tregs 
(165). Moreover, according to an evolving model in the field of immunometabolism, signals from 
the tumor induce a circuitry of glycolysis, Fatty acid synthesis, and oxidation that confers a 
preferential proliferative advantage to Tregs and thus causes their intra-tumoral accumulation 
(166). In addition, it has been suggested that a subclass of DCs in the TME may, in a TGF-β-
dependent manner, stimulate clonal expansion of Tregs (167). 
A variant of Treg plasticity, or tissue-specific adaptations (described above), is observed in tumor-
infiltrated Tregs as they display a unique transcriptional machinery and other properties not 
reported for in Tregs outside of the TME (168, 169). For instance, the suppressive molecule Nrp1 
is upregulated and required for the maintenance of intratumoral Treg stability and function but is 
dispensable for peripheral immune tolerance in mice (170). Also, tumor-infiltrating Tregs (TI-
Tregs) display a high tendency to release perforin and granzyme which may induce apoptosis in 
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NK- and cytotoxic CD8+ T cells (171). Recently, the chemokine receptor CCR8 was found to be 
upregulated in human breast-cancer-resident Tregs which correlated negatively to survival (135). 
It should be noted, that, in contrast to tissue-specific adaptations in the non-cancer setting, the 
changes observed in TI-Tregs appears to result from an exploitation of this subpopulation by the 
tumor rather than from an adequate adaptation into a niche with improved capacity. Consistent 
with this concept, TI-Tregs have been found not only to abrogate tumor immunity but also to 
employ mechanisms that are directly tumor-promoting. For instance, in a mouse model of breast 
cancer, Tregs expressed RANKL which promoted metastasis of RANK-expressing cancer cells 
(172). Also, Tregs have been suggested to stimulate angiogenesis in the TME by secreting 
VEGFA (173).  
The suppressive functions of Tregs normally utilized to protect against autoimmunity have been 
demonstrated to be employed by Tregs also to suppress tumor immunity. For instance, TI-Tregs 
exhibit elevated expression of CTLA-4 which mediates several immunosuppressive effects, 
including interference with DC function (174, 175). In fact, data indicates that the major 
suppressive function of CTLA-4 in the TME is mediated by Treg-bound rather than Teff cell-
bound CTLA-4. These data derive from efforts to clarify the mechanistic basis of how Ipilumimab 
augments the anti-tumor immune response. In this endeavor, numerous mouse- but also patient 
analyses, have demonstrated that the main effect of these antibodies is mediated by a preferential 
depletion of CTLA-4-expressing Tregs through antibody dependent cellular cytotoxicity (95, 96). 
Initially, blockage of CTLA-4 on Teff cells and thereby unplugging an immune checkpoint was 
considered the main mechanism, hence the term “checkpoint blockade”. Perhaps, this group of 
drugs will need a new nickname.  
Increased levels of extracellular adenosine is considered an immunosuppressive factor in several 
cancers (176, 177). These elevated adenosine levels have partly been attributed to Tregs as the 
degradation of extracellular ATP to adenosine is a suppressive mechanism typically employed by 
these cells. The mechanism is mediated by the ectonucleotidases CD39 and CD73, both highly 
expressed on TI-Tregs in, for instance, human head and neck cancers (121, 178). Yet, a 
prerequisite for the generation of extracellular adenosine is the availability of extracellular ATP, 
which is readily secreted by both tumor- and non-tumor cells during hypoxic- and other stress 
conditions (reviewed in (179)). The TME is often subverted by such taxing conditions, creating 
a synergistic Treg-tumor loop which fuels the orchestration of an immunosuppressive 
environment. A central aspect of this synergism may be the differential metabolic set point of 
Teff cells and Tregs. The former suggested to be chiefly glycolytic whereas the latter appear to 
rely also on fatty acid oxidation and thus confers Tregs in the hypoxic TME with both a 
functional- and proliferative advantage (166).  
The above reviewed data gives a one-sided picture of Tregs as suppressors of anti-tumor 
immunity which could beneficially be targeted to improve clinical outcome in cancer. 
Intriguingly, a positive correlation of TI-Tregs to prognosis in several cancers, including UBC, 
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have been reported (135, 180-182). For long, these seemingly paradoxical data have puzzled 
investigators in the Treg field.  
We and others have made attempts to explain these contradictory reports. A first factor to 
consider, is the large variations in how the Treg identity was determined across studies (due to a 
lack of consensus in this regard). For instance, many investigators have determined Treg identity 
primarily based on FOXP3 expression. However, its transient expression also in Teff cells (72) 
renders these studies prone to methodological artifacts, as convincingly demonstrated in patients 
with colorectal cancer (CRC) (183). In this study, by using a function-based scheme to classify 
tumor-infiltrating FOXP3+ cells, it was demonstrated that a fraction of the CRCs were heavily 
infiltrated with FOXP3+ non-Tregs which secreted inflammatory cytokines. Within the patient 
group bearing these FOXP3+ non-Tregs, those patients with non-Tregs displaying a high FOXP3 
expression had a better prognosis than those patients with low FOXP3 expression in these cells. 
Thus, FOXP3 expression is non-Treg specific and FOXP3+ T cells is a heterogonous population 
which can have opposite correlations to prognosis within a single malignancy depending on the 
degree of expression. Most likely, this differential prognostic effect reflects a difference in the 
contribution to tumor immunity by the two FOXP3+ non-Treg subsets.   
While heterogeneity within FOXP3+ T cells might explain the inconsistent data for CRC, this 
model might not be applicable to other cancers where tumor-infiltration by Tregs correlates 
positively to survival. These cancers include UBC, as we have previously reported (135), breast, 
and head and neck cancers (180-182). Because all these cancers are closely linked to chronic 
inflammation, which reportedly drive rather than protect against tumor progression, we and others 
have suggested the positive impact of Tregs in these settings, to be attributed to suppression of 
such unresolved, tumor promoting, inflammation (150, 184).  
1.3.3 Tumor promoting inflammation 
The link between chronic inflammation and cancer was acknowledged already in the 19th century 
by Virchow (185). Thereby, this notion of cancer as “a wound that does not heal”, by far preceded 
the broad acceptance of immunosurveillance as a concept. It is now well substantiated that 
leukocytes infiltrating a tumor may exert both tumor-suppressive and tumor-promoting effects. 
The latter effects are widely implied, in fact, inflammation is considered a principal mechanism 
by which the hallmarks of a cancer cell are developed (6). Adding to the complexity, tumor-
promoting inflammation (TPI) is reciprocal, as inflammation may promote cancer (outside-in) 
but cancer may also promote inflammation (inside-out). 
1.3.3.1 Outside-in 
Unlike most healthy tissue, cancer involves continuous cell renewal and proliferation. The several 
ways by which inflammatory molecules may support such proliferation converge at the level of 
the transcription factors STAT3 and NF‑κB (186). For instance, IL-6 derived from myeloid cells 
activated STAT3 which increased pre-malignant cell proliferation and inhibited apoptosis in a 
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mouse model of colitis-associated CRC (187). In addition, activation of STAT3 by TNF, IL-6 
and IL-1 caused an upregulated production and activity of matrix metalloproteinases (MMPs) in 
breast cancer and melanoma cells (188, 189). MMPs are critical for breaching extracellular matrix 
(ECM) during the epithelial–mesenchymal transition, a central event in the metastatic process 
(190). 
Inflammation may also contribute to carcinogenesis by causing genomic instability and 
mutagenesis. Mechanistically, inflammatory mediators including TNF, IL‑1β and 
prostaglandin.E2 may interfere with the DNA repair machinery (191). Moreover, reactive oxygen 
species derived from macrophages and neutrophils, or induced intracellularly in pre-malignant 
cells by inflammatory cytokines, may directly cause mutations (186, 192).  
1.3.3.2 Inside-out 
Cancer cells may impact immune cells in numerous ways to favor their own progression, as 
described in the previous section where cancer immunoediting was discussed. The inside-out 
model of TPI is an expansion of that concept, where the modulation of the inflammatory response 
by cancer cells is considered as a major dimension of the overall crosstalk between the tumor and 
its microenvironment, including stroma and vasculature. 
For instance, “cancer associated fibroblasts” (CAFs), are former fibroblasts subverted by the 
tumor and abundant in the TME with the capacity to promote macrophage recruitment, 
angiogenesis and tumor progression through NF-kB signaling, in skin cancer models (193). CAFs 
have also been reported to induce MMP activity in head and neck cancer patients (194). 
The tendency of a tumor to tilt the inflammation to its favor is further exemplified by the 
observation that the anti-tumor T cell response may be skewed by cancer cells from a tumor-
suppressive Th1 response, to a tumor-promoting Th2 response (186). In turn, The Th2 CD4+         
T cells, by secretion of IL-4, may skew macrophages towards a type 2 differentiation state, a cell 
subset which potently promotes tumor growth (discussed below). Moreover, tumor cells 
frequently secrete TGF-β, a cytokine with several suppressive effects, including inhibition of 
granzymes and perforin expression in CD8+ T cells (195). Lastly, tumor-derived inflammatory 
mediators, for example prostaglandins, may induce myeloid-derived suppressor cells (MDSCs) 
which may inhibit an anti-tumor T cell attack by TGF-β secretion or by depleting amino acids 
central for T cell function (196). Taken together, by secretion of soluble mediators, the tumor 
creates a distorted network of a wide range of cell types which promotes carcinogenesis and 
eventually metastatic spread.  
1.3.3.3 Tumor associated macrophages 
The macrophage compartment is another abundant myeloid cell type in the TME, their 
accumulation is associated with poor prognosis and treatment failure (197). These tumor- 
 40 
associated macrophages (TAMs) can contribute to immune evasion and play multiple roles in 
promoting metastatic spread.  
Macrophages have been categorized into two types: the M1 type, which are “classically 
activated”, i.e. by IFNγ, Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and 
PRR agonists, express elevated levels of IL‑12 and low levels of IL‑10, and can be tumoricidal 
(198). Tumors may corrupt the M1 type and polarize them to M2 macrophages, which happens 
through stimulation with IL-4, IL-13, IL-10 and M-CSF (198). These molecules may be provided, 
for instance, directly by cancer cells secreting TNFα (199), or indirectly, by skewing Th1 to Th2 
CD4+ T cells, which secrete IL-4 (200). In established tumors, TAMs generally have an M2-like 
phenotype with low IL-12 expression and high IL-10 expression (197). TAMs facilitate tumor 
growth and progression by several modules including immunosuppressive effects such as poor 
antigen presentation because of downregulation of both MHC class I and II molecules (201). 
Moreover, TAMs secrete CCL22 which attracts CCR4-expressing Tregs to the TME (165), which 
theoretically creates a positive feedback-loop since Tregs produce IL-10, necessary for M2 
polarization.  
There is convincing evidence, including intravital imaging, of macrophages to be indispensable 
for tumor cell migration and invasion (202). Several mechanisms employed by TAMs for this 
process have been defined: the overexpression and increased activity of MMPs is a key such 
mechanism (200, 203, 204). MMPs are pivotal for the degradation of normal tissue ECM during 
the course of metastasis (205). Although stroma and cancer cells also produce these proteinases, 
TAMs appears to be the predominant source in several cancers including UBC (206). In UBC, 
high MMP2 expression correlates strongly to decreased survival and the activated form of MMP2 
is higher in invasive than in non-invasive bladder tumors (207). Intriguingly, high levels of CCL2, 
a chemokine which potently stimulates TAM accumulation, correlates with high tumor stage and 
grade in UBC (208).  
Another prometastatic mechanism of TAMs is their secretion of epidermal growth factor, which 
activates the corresponding receptor on cancer cells resulting in an increased invadopodium 
formation and subsequent improved motility and invasive potential (209). Lastly, TAMs were 
demonstrated to stimulate tumor growth through inducing angiogenesis by secreting VEGF in a 
mouse model of breast cancer (210). 
Leukocytes are not evenly distributed within a tumor. This phenomenon has a direct clinical 
relevance because the density of a given immune cell subset will correlate differentially to 
prognosis depending on where in the tumor the subset is located (22). The central part (CP) and 
the IF exhibit particularly distinct immune contextures where the former contains only limited 
types of immune cells whereas the latter is in general highly infiltrated by a plethora of immune 
cells, including macrophages (22). At this location, MMPs modulate the ECM, contribute to 
angiogenesis and cell mobility (211). In agreement, the expression of certain MMPs is most 
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pronounced at this site in both UBC and gastric cancer, which correlates strongly to higher tumor 
grade (206, 212). 
1.3.4 The sentinel node, a key component of the tumor microenvironment 
As discussed previously, immune responses are in general initiated in the lymph node. This notion 
combined with the hypothesis that immunosuppression would be less pronounced in the tumor-
draining lymph node, is the foundation for our groups’ focus on this anatomical location, because 
it represents an alternative source for ACT (143). However, because tumors may induce 
neolymphangiogenesis, the lymphatic drainage system is frequently deranged which complicates 
the identification of this node(s). This has been solved by using a method in which a radioactive 
tracer is injected adjacent and around the tumor (Figure 2), which enables to identify the first 
node of a primary tumor on the direct lymphatic drainage system, referred to as the sentinel node 
(213). This method has long been established for melanoma and breast cancer and more recently 
also been introduced for UBC (214). The SN offers a rare opportunity to study the direct 
communication between the tumor-and the immune system, with access to relevant control nodes, 
namely non-tumor draining non sentinel nodes (nSNs). In such interrogations, a high degree of 
immunosuppressive elements, including Treg accumulation, have been reported in the SN relative 
to nSNs (reviewed in (215)). To improve the efficacy of SN-based ACT, increased knowledge of 
the dominating escape mechanisms in this compartment is needed. 
 
Figure 2. Sentinel node detection. 
Schematic illustration of 
intraoperative sentinel node 
detection in urinary bladder 
cancer. Following peritumoral 
injection of a radioactive tracer, 
the first lymph nodes (purple) to 
drain the tumor are detected by 
using a probe. Figure courtesy of 
Malin Winerdal. 
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1.3.5 Effects of chemotherapy on tumor immunity 
Widespread evidence exists that the efficacy of conventional chemotherapy does not only stem 
from the direct cytostatic/cytotoxic properties, but also relies on positive immunomodulatory 
effects (reviewed in (22, 216)). The origin of these immune effects may be “On target”, meaning 
that they result from drug actions on the cancer cells. Such activity boosts the immunogenicity of 
the tumor through either increasing its antigenicity or its adjuvanticity, or both thereof (216). 
Alternatively, the immunostimulatory effects of chemotherapeutics may be "off-target," which 
refers to effects originating from drug actions on the immune system. Off-target effects may be 
direct, i.e. activation of immune effector cells or indirect, referring to inhibitory effects on 
immunosuppressive cells (216). Here follows a brief, T cell-centric, discussion of these 
immunogenic “side effects” of chemotherapies and how they may be used in conjunction with 
cancer immunotherapies. 
1.3.5.1 On-target - Increased immunogenicity 
The triggering of cancer cells to undergo immunogenic cell death (ICD) is the core mechanism 
by which chemotherapeutics may increase the immunogenicity of a tumor. ICD can involve the 
activation of both apoptotic and necroptotic (a programmed form of necrosis) pathways resulting 
in cell death (217). ICD-associated pathways may yield increased antigenicity, for example 
through exposure of the endoplasmatic reticulum (ER) protein calreticullin on the tumor cell 
surface. Calreticullin act as a major “eat me” signal to DCs, subsequently supporting the 
engulfment and transfer of tumor antigens to these APCs (218).  
The ICD process is also accompanied by the release of DAMPs such as annexin A1, HMGB1 
and ATP, with the former acting on formyl peptide receptor-1 (219), and the latter two binds to 
their respective PRR; TLR4 and the purinergic receptor P2RX7. These DAMPs potently reinforce 
the adaptive anti-tumor immune response, exemplified with their capacity to activate the NLRP3 
inflammasome, which is particularly versatile, leading to IL-1b secretion and activation of IFNγ-
secreting CD8+ T cells. ICD has also been reported to increase tumor antigen cross-presentation 
and cross-priming of host tumor-specific CD8+ T cells (220). 
These ICD pathways have been delineated in mouse models but are supported by human data. 
Phosphorylation of eukaryotic translation initiation factor 2 subunit alpha (eIF2α) during ER-
stress is a marker proposed to be pathognomonic for ICD (221). Low levels of eIF2α 
phosphorylation in human breast cancer tissue following chemotherapy correlate with a low CD8+ 
T cell to FOXP3+ cell ratio and with poor responses to NAC (222). Stressing the possible clinical 
relevance of these pathways, loss-of function polymorphisms in TLR4 and P2RX7 are associated 
with an increased risk of breast cancer relapse after adjuvant anthracycline-based chemotherapy 
(128, 223). Similar findings have been reported for TLR4 in head and neck cancer (224).  
Non-ICD dependent mechanism favoring antigenicity have also been described, where restored 
MHC class I expression appears as a main mechanism in both mice and men (225).  
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1.3.5.2 Off-target – direct and indirect immunostimulation 
A prerequisite for the “On-target effects” to be of any use, is the presence of immune effector 
cells with a capacity to be (re)activated and ultimately implement an anti-tumor immune response. 
We previously reported on a direct positive effect on immune cells upon chemotherapy, namely 
of cisplatin to augment the immune stimulatory activity of DC differentiating human monocytes, 
resulting in an increased T cell proliferation (226) and of Doxorubicin to enhance the antigen 
presenting capacity of B cells (appended paper II). Correspondingly, cyclophosphamide shifts the 
CD4+ Th phenotype from type 2 to type 1, and promotes durable CD8+ T-cell memory responses 
capable of eradicating tumors upon rechallenge, in mouse tumor models (227, 228). 
There is plenty evidence of chemotherapy to induce indirect immunostimulation, i.e. through 
inhibition of immunosuppressive circuits, but mostly derived from rodent tumor models. For 
instance, 5-fluorouracil, cyclophosphamide, gemcitabine, oxaliplatin, paclitaxel and docetaxel 
have all been demonstrated to deplete circulating or TI-Tregs and/or circulating MDSCs 
(reviewed in (225)). These findings are supported by patient data comprising various 
malignancies including non–small cell lung carcinoma, where a reduction of Treg frequency in 
peripheral blood upon gemcitabine plus cisplatin chemotherapy was reported (229). Moreover, 
cyclophosphamide, when administered in metronomic doses, selectively depletes Tregs in late 
stage cancer patients (230). In consistency, breast cancer patients treated with NAC displayed an 
increased CD8+ T cell to FOXP3+ T cell ratio which was associated with improved recurrence 
free survival and outperformed conventional predictive factors (231) or predicted NAC response 
(222). 
The fact that chemotherapy-induced alterations of immunosuppressive cells is a relative common 
finding, together with the tendency of these drugs to increase the Teff cell to Treg ratio, suggest 
that immunosuppressive cells, at least in certain contexts, are more sensitive to cytotoxic agents 
compared to Teff cells and thus are selectively depleted. However, given the opposite roles in 
tumor immunity implied for Tregs, it is reasonable that a Treg-inhibiting effect of 
chemotherapeutics is not always desirable. 
1.3.5.3 Combining chemotherapy and immunotherapy  
The major effects of chemotherapy on tumor immunity have started to be taken in to account in 
the effort of developing new immunotherapies but also in the pursuit to develop integrated 
treatment protocols for already existing chemo- and immunotherapies, striving to avoid 
antagonistic effects and, in the best of worlds, achieving synergism. One example is an ongoing 
phase III trial of the TG4010 cancer vaccine containing viral vectors encoding for IL-2 and the 
tumor antigen mucin-1, and first-line gemcitabine- and cisplatin-containing chemotherapy for 
advanced non-small-cell lung cancer. Data from the phase 2b part indicate that the combinatory 
use of TG4010 and chemotherapy improves progression-free survival compared to placebo plus 
chemotherapy (232).  
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The limited response rate of checkpoint blockers have sparked an interest to integrate the use of 
these drugs with immunogenic chemotherapy. A recent study using a novel approach to block 
PD-L1, namely by using an engineered, locally and transiently expressed “PD-L1 trap” was tested 
together with oxaliplatin in the setting of murine CRC (233). Indeed, synergistic effects were 
achieved and with a tendency of fewer adverse effect compared to when using anti-PD-L1 mAb. 
Moreover, chemotherapy may reportedly sensitize tumors to checkpoint blockade in mouse lung 
adenocarcinoma because cyclophosphamide/oxaliplatin induces TLR4 signaling which results in 
tumor influx of CD8+ T cells and, upon checkpoint inhibition, durable tumor control (234). The 
clinical translation of these findings is emerging. For example, there is an ongoing phase II study 
where both PD1/PDL1- and CTLA-4 blockade is tested in combination with standard 
chemotherapy in patients with metastasized CRC, preliminary results are yet to be published 
(235). 
1.3.6 Antigen presenting B cells in cancer 
The antigen presenting function of B cells is usually considered, if considered at all, in the context 
of the CD4+ Th cell-B cell interaction, necessary for isotype switching. However, B cells are 
professional APCs along with DCs and macrophages and, in certain settings, they have the ability 
to prime naïve T cells and initiate T cell responses. The following passages will briefly describe 
this topic and also touch upon the relevance of B cells in the cancer setting.  
1.3.6.1 B cells as specialized APCs 
Upon capturing an antigen, APCs may internalize it by three means: phagocytosis, fluid-phase 
pinocytosis, and receptor-mediated endocytosis. In B cells, the last process is favored and carried 
out by the BCR (reviewed in (236)). Because the BCR has high affinity for a given antigen, B 
cells can concentrate minute quantities of their specific antigen and present it efficiently. This 
notion is supported by demonstrations of a direct relationship between BCR affinity and antigen 
presentation, where B cells may present antigens of concentrations as low as 0.05 nM (237, 238). 
In contrast, 5000 times higher concentrations were required if the antigen uptake occurred through 
the fluid phase pinocytosis route.  
The binding of the BCR to its antigen induces its internalization through the endocytic pathway 
(Figure 3, upper part) but it also initiates cell intrinsic signaling necessary for mobilizing the 
antigen processing machinery (239). This coupled mode of action, ultimately favors antigen 
presentation initiated by the BCR over other means of antigen capturing.  
The antigen-containing endosomes acidify as they traffic inside the cell and fuse with lysosomes. 
In these fused compartments, MHC II molecules are abundant, and here peptide–MHC II 
complex formation take place. The acidification induces proteolytic degradation of the antigens 
into peptide fragments. In the vesicular compartments, processed peptide fragments are then 
loaded on the MHC class II pockets upon which the peptide–MHC II complexes traffic to the 
plasma membrane. During this process, the high affinity of the BCR to its epitope again has  
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Figure 3. Schematic overview of antigen capture and presentation by a B cell. Upper part: 
Antigen is captured by the B cell receptor and internalized via receptor-mediated endocytosis, 
processed and loaded on to an MHC class II molecule, forming the MHC class II-peptide complex 
which traffics to the plasma membrane. Lower part: Three signals contribute to complete 
activation of both B and T cells; 1.) MHC class II-peptide interaction with the T cell receptor 
complex. 2.) Binding of costimulatory molecule such as CD86 to its CD28 receptor. 3.) Cytokine 
secretion (green and yellow dots). Figure courtesy of Malin Winerdal. 
 
implications, as this part of the antigen in general is not released, thus not processed and presented 
(240). In this way, the BCR configuration dictates, or shapes, the immune response.  
In addition to expressing the peptide–MHC II complex, other tools such as the upregulation of 
costimulatory molecules are necessary to activate naïve T cells. This, in turn, requires the 
binding of CD40 (expressed on the B cell) to its ligand, CD40-L, expressed by activated CD4+ 
T cells. Due to this restriction, the contribution of B cells to prime naïve CD4+ T cells have 
been questioned. However, there is evidence suggesting that B cells are able to elicit CD40-L 
expression on T cells during their own activation. For instance, when transferring antigen-
specific B and CD4+ T cells into histoincompatible lymphocyte-deficient mice, presentation of 
the antigen by B cells resulted in the priming of naïve CD4+ T cells in a CD40-L dependent 
manner (241). In a proposed model (236), a strong or durable BCR signal induces a bidirectional 
cross-talk process between the B cell and naïve CD4+ T cell ultimately resulting in the ability 
of the B cell to provide all three necessary signals to activate a T cell with the corresponding 
antigen-specificity (Figure 3, lower part); 1) the expression of MHC class II-antigen complex 
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to which the T cell receptor binds, 2) the expression of costimulatory molecules such as CD86 
and CD40 which binds to the CD28 T cell surface receptor and T cell-bound CD40-L 
respectively and 3) the secretion of cytokines, such as IL-2, IFN-γ or IL-4, which bind to their 
respective receptors. 
 
1.3.6.2  Conventional and regulatory B cells in cancer 
In analogy with the conflicting data on Tregs, some studies report B cells to promote tumor 
immunity whereas others point on a suppressive, negative role. An example of the former is our 
previous demonstration of a clonal expansion of B cells in tumor-associated lymph nodes as well 
as in the tumor of bladder cancer patients (242). In line with these data, TIL-Bs in non–small cell 
lung cancer patients were recently reported to present antigens to TIL-CD4+ T cells and  to affect 
the phenotype of these CD4+ T cells, as demonstrated in ex vivo co-culture assays (243). TIL-Bs 
appears to preferentially be organized together with CD4+ T cells in tumor-adjacent lymphoid 
islets, called tertiary lymphoid structures (244). These structures correlate positively with survival 
in non-small-cell lung carcinoma. Additionally, mouse studies have demonstrated TIL-Bs to 
produce tumor-antigen specific antibodies (245). Combined, these data indicate a protective role 
of TIL-Bs also in this malignancy.  
On the other side of the coin, a recently defined immune suppressive B cell subpopulation dubbed 
Regulatory B cells (Bregs) have been suggested to oppose tumor immunity (reviewed in (246)). 
These cells not only share suppressive effector mechanisms with Tregs, namely the secretion of 
IL-10, TGF-β and IL-35, they have also been reported to facilitate the generation of Tregs (247). 
Although the role in humans is not well defined, emerging data indicate the negative role 
described in the murine setting to be translatable. Breg frequency was reported to correlate 
negatively to survival in some cancers including tongue squamous cell carcinoma (247). 
Mechanistically, a tumor-promoting role in hepatocellular carcinoma (HCC) have been described 
where Bregs were demonstrated to support HCC cell growth via the CD40/CD40-L pathway 
(248). Taken together, much remains to be learned of the role of B cells in cancer, and their impact 
on tumor immunity is likely underestimated, considering their sovereignty as APCs in contexts 
with limited amount of antigen.   
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2 AIMS OF THIS THESIS 
The overarching aim of this thesis was to elucidate how lymphocytes and cancer cells sculpt 
each other and what effect standard chemotherapy has on this process, with the purpose to 
identify targets for immunotherapy. 
 
Paper I. To clarify if the tumor-infiltrating CD4+FOXP3+ T cell population in urothelial 
bladder cancer patients confer a stable Treg phenotype and to disclose the role and biological 
impact of Tregs on this cancer, focusing on tumor-promoting inflammatory pathways.  
Paper II. To elucidate the effect of chemotherapeutic drugs on human B cells with a special 
attention on their function as APC’s. 
Paper III. To elucidate the effects of neoadjuvant chemotherapy on T cell subsets in the 
sentinel nodes of MIBC patients with emphasis on phenotype, function and subset composition 
and their correlation to NAC response. 
Paper IV. To explore if the proteome in SN-resident T cells is altered by the tumor and to 
identify key proteins in SN T cell signaling, focusing on Tregs. 
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3 MATERIALS AND METHODS 
3.1 PATIENTS 
3.1.1 Patient characteristics (Paper I-IV) 
All papers encompass patients with UBC, prospectively included at one of the collaborating 
study centers between 2013 and 2017.  
In paper I, 52 patients with suspected MIBC were initially included at the time of TURBT. 
Exclusion criteria were other histopathological malignancy than urothelial, benign neoplasia 
and/or previous BCG treatment. Six patients were excluded and, thus, 46 patients were 
included for downstream analysis. Of these, 28 patients had MIBC and 18 had NMIBC. The 
mean age at the time of diagnosis was 69 years (median 72.5 years) and the male:female ratio 
was 2.5:1. 
In paper II and III, patients were included both at the time of TURBT and at RC. All included 
patients in these studies had confirmed MIBC. Paper II included 15 patients with an age range 
of 55-86 and a male:female ratio of 2.75:1. Five patients had been treated with a doxorubicin-
containing NAC. The 40 patients included in paper III had a mean age of 69 (median 70.5 
years) and a male:female ratio of 3:1. 1-4 cycles of Cisplatin-based NAC was administered to 
fit patients pre-RC (n=27) except for one patient who received carboplatin-gemcitabine.  
In paper IV, five patients with confirmed MIBC and an age range of 58-85 were included. 
3.1.2 Surgical methods, sentinel node detection and collection of specimens 
(Paper I-IV) 
At the TURBT, peripheral blood, tumor tissue samples and cold-cup biopsies from 
macroscopically healthy bladder tissue were obtained. Whenever feasible, tissue from the CP 
and IF of the tumor were collected separately. SN detection was performed just prior to 
cystectomy by transurethral injection of 80 Mbq Technetium adjacent and around the tumor 
border. Thereafter, SNs and non SNs (nSNs) were identified both in vivo and ex vivo.  
Tumor tissue and SNs were immediately immersed in ice-cold RPMI medium in the surgery 
room, followed by prompt transportation to the laboratory for immediate processing. The 
overall workflow, including the cell preparation and subsequent flow cytometry analysis, is 
depicted in Figure 4. 
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Figure 4. Overall workflow of specimen collection and flow cytometry analysis, paper I-IV. 
(Left panel) At the time of TURBT or cystectomy, patient specimens were collected including 
(middle panel, top) peripheral blood, (center) lymph nodes and (bottom) tumor tissue from 
distinct tumor sublocations, as indicated. From these specimens, lymphocytes were extracted 
and processed into single cell suspensions, which were labeled with fluorescently-conjugated 
antibodies and analyzed by (right panel) multicolor flow cytometry. The basic principle of this 
method is the passage of single cells in a stream to which a beam of laser (green) is directed. 
The fluorescently labelled cell components are then excited by the laser and emit light at a 
longer wavelength (red), which reaches a detector, enabling to quantify the amount and type of 
cells present in a sample. CP= Central part, IF= Invasive front. Figure courtesy of 
 Malin Winerdal. 
3.1.3 Patient follow-up (Paper I,III and IV) 
In study I, Treg frequency was correlated to Overall survival (OS), calculated from the time of 
TURBT with a median follow-up time of 3.5 years. In study III, NAC-response was assessed 
by histopathological staging post-RC and categorized as: complete response, CR, (pT0N0M0), 
partial response; PR, (pTa/pTis/pT1-N0M0), and no response; NR, (≥pT2-N0M0). In study III 
and IV, six respectively one patient had nodal dissemination (pN1), as detected by the routine 
clinical pathological analysis. Due to the small sample size, these metastatic nodes were 
excluded from all of the immunological status- (paper III) or proteomic analyses (paper IV). 
3.2 CELL ISOLATION, PREPARATION AND CULTURE (PAPER I-IV) 
In all studies, Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized 
peripheral blood or buffy coats (paper I, II and IV) by density centrifugation gradient (Ficoll–
Paque PLUS Amersham Biosciences). Lymph node leukocytes were extracted (paper III and 
IV) by gentle homogenization through a 40 µm cell strainer. TILs, were isolated (paper I) by 
cutting the tumor into small pieces (approximately 1–2 mm in diameter), put into AIM-V 
medium (Gibco, Life Technologies) with collagenase/hyaluronidase (Stemcell Technologies), 
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processed in a gentleMACS dissociator (Miltenyi Biotec) and strained through a 40µm cell 
strainer.  
Lymphocyte populations of interest were isolated using magnetic sorting (isolation kits from 
either Stemcell Technologies or Miltenyi Biotec) alone or in combination with FACS-sorting. 
All isolated cell populations were confirmed > 90 % pure, using FACS.  
In paper I, M2-like macrophages were generated from healthy donor PBMC-derived CD14+ 
monocytes according to the protocol described by Mia et al. (249). Briefly, monocytes were 
pre-differentiated into macrophages by culture for 6 days in RPMI 1640 supplemented with 50 
ng/ml of M-CSF. In parallel, autologous FACS-sorted Tregs were activated in vitro using Anti-
Biotin beads preloaded with biotinylated CD2, CD3, and CD28 Antibodies (Miltenyi Biotec). 
At day 6, Tregs were added to the M2-like macrophage containing wells at different 
Treg:macrophage cell ratios.  
In study I and IV, all cell culture steps following cell isolation were carried out in RPMI 
medium supplemented with 10% fetal calf serum (FCS), 1% glutamine, and 1% 
penicillin/streptomycin (complete RPMI). In paper II and III, AIM V supplemented only with 
L-glutamine was used for the adapted Flow cytometric Assay for Specific Cell mediated 
Immune response in Activated whole blood (FASCIA) experiments. 
3.3 IMMUNOLOGICAL EVALUATION 
3.3.1 Flow cytometry (Paper I-IV) 
3.3.1.1 Surface and intracellular staining 
Surface epitopes were stained using combinations of fluorochrome-labelled antibodies. 
Intracellular FOXP3 and cytokine staining was performed subsequently to surface staining, 
using the FOXP3 staining buffer kit from eBioscience according to the manufacturer’s 
protocol. For a detailed account on the FACS antibodies used, please refer to the methods 
section of the respective papers I-IV. As there indicated, isotype- and fluorochrome matched 
control antibodies were used to define marker positivity. Acquisition of data was performed on 
a FACS LSR Fortessa II (paper I, III and IV) or on a FACS Aria I (paper II) (BD Biosciences). 
The flow cytometry data was analyzed using FlowJo X 10.0 7r2 (paper I, III and IV) or 
FACSDiva (paper II).  
3.3.1.2 Sorting (Paper I, III and IV) 
Flow cytometry sorting was carried out to isolate CD4+ Teff cells and Tregs for T cell function 
experiments (paper I and IV), epigenetic- (paper I) and proteomic analysis (paper IV). Also, in 
paper III, CD8+ T cells were FACS-sorted for epigenetic analysis. All sorting was carried out 
on a FACS Aria (BD Biosciences). Post sort purity was confirmed at > 90%, using flow 
cytometry. 
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3.3.1.3 Cytokine analyses (paper I, II and IV) 
In paper I, II and IV, isolated lymphocyte populations of interest were stimulated with Phorbol 
Myristate Acetate (PMA) and Ionomycin. Brefeldin A (GolgiPlug) was added 1 h after 
stimulation. Cells were harvested 6 h after stimulation for surface- and subsequent intracellular 
staining following FACS analysis. In paper II, also secreted, extracellular, cytokines were 
quantified by Luminex 14-plex analysis of the supernatant of cell cultures containing blocked 
CD86 B-cells or control supernatant. 
3.3.1.4 Phosflow (Paper I) 
Phosflow intracellular staining was carried out according to the manufacturer's protocol 
(Beckton Dickinson phosflow protocol III for human PBMCs). Briefly, isolated CD4+ T cells 
were stimulated with IL-2 at indicated concentrations and subsequently fixated and then 
permeabilized using the recommended buffers. Upon incubation on ice for 30 min, the cells 
were stained for 60 minutes at room temperature with fluorochrome-conjugated antibodies 
against pSTAT5, relevant surface molecules, and FOXP3 prior to analysis by flow cytometry. 
3.3.2 T cell function assays (I-IV) 
3.3.2.1 Flow cytometric assay of cell mediated immune response in activated lymphocytes 
(paper II and III) 
For evaluation of cellular activation upon stimulation with tumor antigen, 5x105 cells from 
peripheral blood (paper II) or SNs (paper III) were cultured with tumor homogenate as 
described by Marits et al. (250). Activated, blasting, cells were identified based on their 
position on forward- and side-scatter dot-plots. The tumor specific response was quantified by 
using macroscopically healthy bladder or medium alone as control and calculating a 
stimulation index (SI) according to the following formula: 
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3.3.2.2 Treg suppression assay (paper I) 
Responder cells (Teff cells) were labeled with Carboxyfluorescin diacetate succinimidyl ester 
(CFSE) and 1 x 105 cells/well were co-cultured with Treg cells at indicated ratios in the 
presence of Treg Suppression Inspector Anti-Biotin beads preloaded with biotinylated CD2, 
CD3, and CD28 antibodies (Miltenyi; beads:cells 1:1) in 96-well plates for 72 hours. CFSE 
dilution was measured by flow cytometry.  
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3.4 EPIGENETICS (PAPER I AND III) 
3.4.1 Genomic DNA isolation and Bisulphate conversion 
Genomic DNA was isolated from FACS-sorted T cell populations which in turn had been 
isolated from tumor (paper I), SNs, non-SNs (paper III) and peripheral blood (paper I). The 
isolation was performed as an on-column step on the EZ DNA Direct- Methylation kit (ZYMO 
research).  
Bisulfite treatment of genomic DNA results in the conversion of unmethylated cytosine 
residues to uracil, which are recognized as thymines in subsequent PCR amplification. 
Cytosines that were originally methylated remain intact, thereby enabling distinction between 
methylated and unmethylated residues (251).  
3.4.2 Pyrosequencing 
The FOXP3 target sequences (paper I) and the IFNG and PRF gene loci (paper III) were 
amplified by PCR of the bisulfite-converted DNA samples using biotinylated primers. 
Biotinylated PCR products were purified with a Pyromark Q96 Vacuum Workstation (Qiagen), 
and subsequently pyrosequenced using a Pyromark Q96 ID instrument (Qiagen). Data analysis 
was performed using Pyromark Q96 software (Qiagen). 
3.5 PROTEOMICS (PAPER IV) 
Frozen cell pellets were thawed on ice, sonicated and cell debris was removed by 
centrifugation. 5 µg of protein underwent denaturation followed by tryptic digestion overnight 
and subsequent clean-up. For a detailed description of these procedures, please refer to the 
appended paper. 1 µg of the resulting peptide mixture was loaded onto a nano-Ultimate HPLC 
system with an acetonitrile gradient (Thermo Scientific) in-line coupled to a QExactive orbitrap 
mass spectrometer (Thermo Scientific). The chromatographic separation of the peptides was 
achieved using a 28 cm long in-house packed column (C18-AQ ReproSil-Pur®) with an 
acetonitrile gradient.  Tandem mass spectra were extracted using Raw2MGF and the resulting 
mascot generic files were searched against a SwissProt protein database using Mascot software 
(Matrix Science Ltd.). Peptides were quantified using the Quanti software (252), which 
performs label-free quantitation of the ion current for each MS/MS spectrum. It also excludes 
peptides identified with a Mascot score of 16 or lower, enabling to fulfill the false discovery 
condition (no more than 1 %).  
3.6 WESTERN BLOT (PAPER IV) 
Cultured cells were pelleted, washed and incubated in RIPA buffer. Upon centrifugation for 15 
minutes at 8000 RPM, the supernatant (protein fraction) was collected and pellets discarded. 
Protein concentration was measured using BCA assay (ThermoFisher). 12,5 µg protein per 
well was loaded onto 4-12 % Bis-Tris gels (Life technologies) and gels were run according to 
manufacturer’s protocol. Proteins were transferred for 45 minutes at 30V to PVDF membranes 
(Bio-Rad), blocked with 2.5 % BSA in PBS-T for 1 hour and incubated overnight at 4 C⁰ with 
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primary antibodies. All antibodies used were diluted in blocking solution. Please refer to the 
paper for list and detailed description of the used antibodies. 
3.7 QUANTITATIVE PCR (PAPER I AND IV) 
Total RNA from macrophages and UBC 5637 cells (paper I) and from T cells (paper IV) was 
extracted using the RNeasy mini kit (Qiagen). cDNA was synthesized using iScript 
complementary DNA synthesis kit (Bio-Rad Laboratories). Quantitative real-time PCR (RT-
PCR) was performed using qPCR SYBR select mix (Life Technologies) and analysis using the 
CFX 96 Real Time System (Bio-Rad Laboratories) with GAPDH as housekeeping gene. 
Relative quantification of the RT-PCR data was calculated using the Pfaffl method. Primer 
sequences are specified in the respective papers. 
3.8 STATISTICAL ANALYSIS  
To test if the test data had an underlying normal distribution, Shapiro Wilk´s test or 
Kolmogorov-Smirnov’s test of normality was used. For such, parametric, data, two-tailed  
t tests or one-way ANOVA was used to compare groups with approximately equal variances, 
whereas Mann–Whitney U test or Kruskall–Wallis one-way analysis of variance with Dunn 
test was used for nonparametric data sets. Repeated-measures ANOVA was used for related 
samples (paper I), together with Bonferroni or Dunnet multiple comparison's tests. The 
Kaplan–Meier method was used to estimate survival rates (paper I). Differences were 
compared using the log-rank test. P values < 0.05 were considered significant.  
In paper I, the impact of Treg frequency on gene expression was estimated by standardized 
coefficients from partial least squares (PLS) analysis. Data from the PLS analysis was plotted 
against the KEGG pathway for bladder cancer using the free software environment ”R”. 
Statistical calculations were carried out with Statistica [StatSoft, Inc. (2013), STATISTICA 
(data analysis software system), version 12 (www.statsoft.com)] and Prism v.5 software 
(GraphPad), which also was used to construct graphs. 
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4 RESULTS AND DISCUSSION 
The four articles in this thesis all address the role of lymphocytes in patients with urothelial 
bladder cancer. The thesis can be divided into two major topics: i) tumor-Treg cross-talk (paper 
I and IV) and ii) effects of chemotherapy on lymphocytes in bladder cancer patients (paper II 
and III). The intent with the following sections is to facilitate the readers’ understanding of 
what was studied in the papers and why, as well as the general implications of our findings. 
For methodological details and more specific discussion of the results, please see the appended 
papers. 
4.1 UNTANGLING A PARADOX – TREGS HOLD BACK THE INVASIVE FRONT 
(PAPER I) 
The starting point for this study was our preceding finding of a positive correlation between 
Treg tumor-infiltration and prognosis in bladder cancer (135). This was a somewhat 
controversial finding since, at that time, the view of Tregs as unmitigated suppressors of tumor 
immunity was rather unchallenged. In the mentioned study, Tregs were defined according to 
FOXP3 expression status. However, FOXP3 is not exclusively expressed in Tregs but may be 
transiently expressed upon activation in Teff cells (72). Bearing in mind the inflammatory 
milieu in the bladder tumor tissue, mistaking activated T effs transiently expressing FOXP3 for 
Tregs would have been plausible. In paper I, we set out to test this hypothesis.  
Patients (n=52) with suspected UBC were prospectively included. We examined and compared 
T cells extracted from tumor and peripheral blood of patients and of healthy controls, using a 
broad range of analytical approaches.  
We first confirmed CD4+FOXP3+ T-cells to be substantially accumulated in the tumor tissue, 
accounting for over 20 % of the CD4+ T cell population, compared to the corresponding 3 % 
in peripheral blood of healthy donors. In our initial characterization of the tumor-infiltrating 
CD4+FOXP3+ T cell population, we used a set of established markers of Treg memory 
(CD45RO), activation (HLA-DR and CD69), and effector functions (CTLA-4 and CD39 ) (26). 
The two latter markers are key molecules for Treg-mediated suppression in the physiologic 
setting (26) and suggested to be essential for Treg function in cancers (175). We demonstrated 
that the fraction of cells expressing these functional markers on the cell surface, as well as the 
activation marker HLA-DR, was markedly higher among tumor-infiltrating  
CD4+FOXP3+ T cells compared with peripheral blood. The phenotypic analysis thus indicated 
Treg suppressive function at the tumor site. 
The majority of the CD4+FOXP3+ and the CD4+ FOXP3- tumor-infiltrating T cells, were 
activated and antigen experienced as reflected by their prevalent expression of CD69 and 
CD45RO respectively. Intriguingly, also CD39 was abundantly expressed among the tumor-
infiltrating CD4+ FOXP3- subset and it is tempting to speculate that at least a fraction of these 
cells represents pTregs which reportedly may lack FOXP3 expression (253).  
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As a side note, the observed prevalent CD45RO expression among the circulating 
CD4+FOXP3+ T cells implies that these cells are actual Tregs as opposed to activated Teff cells 
transiently expressing FOXP3. This is implied because in adults, the majority of circulating 
Tregs are antigen experienced - in contrast to Teff cells (88).  
To further establish that the tumor-infiltrating CD4+ FOXP3+ T cells were actual Tregs, we 
investigated functional Treg attributes - which are key to validations of Treg populations. Tregs 
have a markedly lower threshold for IL2-induced STAT5 phosphorylation compared to other 
T cell subsets. Thus, assessing pSTAT5 expression upon IL-2 stimulation enables to 
discriminate Tregs from CD4+ Teff cells. Indeed, using phospho-flow cytometry, we show that 
IL-2-induced signaling in the tumor-infiltrating CD4+FOXP3+ cells resembles that of the 
CD4+FOXP3+ Tregs in peripheral blood and differ dramatically from the tumor-infiltrating 
CD4+FOXP3- cells. 
Next, we demonstrated that the tumor-infiltrating CD4+FOXP3+ cells bore a Treg-
characteristic cytokine profile with negligible production of the pro-inflammatory cytokines 
IFNγ and IL-2. Moreover, we demonstrated the tumor-infiltrating CD4+FOXP3+ cells to 
readily suppress autologous CD4+ Teff cells in a dose-response manner, a hallmark of Treg 
function. Taken together, these findings provide evidence of the tumor-infiltrating 
CD4+FOXP3+ population to functionally act as Tregs in human bladder cancer patients.  
As previously discussed, the Treg-specific epigenome is indispensable for commitment to the 
Treg lineage (253) and is defined by hypomethylation of different regions in key genes or their 
enhancers, often referred to as Treg cell-specific demethylated regions, or TSDR’s. We have 
previously identified the CpG position -77 of the FOXP3 promoter as such a region (48) and, 
similarly, Floess and colleagues (51) found the conserved noncoding sequence 2 (CNS2) of the 
FOXP3 gene to correlate strongly to stable FOXP3 expression. Indeed, in the present study, 
we found these two TSDR’s to be hypomethylated in the tumor-infiltrating CD4+FOXP3+ 
population. From this finding, together with the observed stable FOXP3 expression in long-
term ex vivo cultures, we concluded that these cells are stably committed to the Treg lineage.  
Having confirmed that the CD4+FOXP3+ T cells infiltrating UBC tissue phenotypically, 
functionally, and epigenetically were Tregs, the seemingly paradoxical prognostic benefit of 
this immunosuppressive cell population remained to be explained. Since the spatial distribution 
of immune infiltrates has been noted to differ also within the tumor itself, we examined the IF 
and the central part CP of the tumor separately. We found that the fraction of Tregs was 
significantly decreased at the IF compared to the CP in muscle invasive tumors. In patients 
with non-muscle invasive tumors no such decrease was observed. In agreement, we showed 
that high Treg frequency specifically at the IF gave a clear survival benefit compared to patients 
with a low Treg frequency (100 % vs. 25 % 3-year survival). These findings highlight that the 
impact of Treg frequency on prognosis not only differs between tumor types but also within 
different parts of the individual tumor. Additionally, the data suggest inhibition of invasion as 
a protective mechanism for Tregs in MIBC. 
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To investigate this, we examined the transcriptome of tumor samples from the IF and the CP 
in conjunction with flow cytometric data on Treg frequency. Since other cancers where Tregs 
have been reported to be protective are, similarly to UBC, linked to chronic inflammation (180, 
181) we focused on factors known to be involved in TPI, such as MMPs.  
We identified MMP2 as a gene highly influenced by Treg frequency, using the statistical 
methods specified in the paper. MMP2 was also, out of the 10 MMPs frequently described in 
the cancer setting, the MMP with the highest expression at the IF (254). MMP2 was further 
validated as an invasive factor in UBC. Extracting data from nine previously published 
independent datasets in the ONCOMINE database, revealed an upregulation of MMP2 in 
invasive tumors compared to superficial counterparts. In addition, MMP2 expression has been 
observed in both tumor cells and in TAMs (190, 255). We confirmed this pattern by 
immunohistochemical co-stainings of MMP2 and FOXP3 in UBC tissue. Moreover, MMP2 
staining tended to be scarce in the area surrounding FOXP3+ TILs. These findings prompted 
us to evaluate if Tregs regulate MMP2 expression in tumor cells or in cells mediating TPI such 
as M2 macrophages. By co-culturing Tregs with either autologous M2 macrophages or the 
invasive UBC cell line 5637 cells, we demonstrated a dose-dependent Treg-mediated 
downregulation of MMP2 protein and mRNA expression in both these cell types.  
The main limitation of this study is that the sample size for the above described functional 
assays is small (n ranging from 2-5). Although the results were consistent through the 
replicates, additional experiments would help to validate these data. 
This work describes a novel functional mechanism of Tregs in tumor biology and offers an 
alternative explanation to the paradoxical benefit of Tregs in certain cancers. Our findings 
highlight the need for caution in the clinical use of immunotherapies targeting Tregs but also 
identify the Treg-MMP2 axis as a potential therapeutic target in inflammation driven cancers. 
4.2 DOXORUBICIN ENHANCES THE CAPACITY OF B CELLS TO ACTIVATE  
T CELLS IN UROTHELIAL URINARY BLADDER CANCER (PAPER II) 
The potential of conventional chemotherapy to enhance an anti-tumor immune response is 
being increasingly recognized (reviewed in (216, 225)). Although much remains to be learned, 
this beneficial “side effect” appears to, in part, depend on an increased antigenicity at the tumor 
site, elicited by certain chemotherapeutic agents (225). In line with these findings pointing at 
antigen presentation as a main factor, we have previously demonstrated that chemotherapy 
treatment during DC differentiation of human monocytes augments the immune stimulatory 
activity of these cells (226). Since B cells also may present tumor antigens to T cells (236), we 
addressed this cell type when shifting focus to the adaptive arm of the immune system. Hence, 
the aim of this study was to elucidate the effect of chemotherapeutic drugs on human B cells 
with a special attention on their function as APC’s.  
Fifteen MIBC patients were prospectively included in the study. PBMCs were extracted from 
blood samples collected at the time of TURBT and at the cystectomy or from healthy donors 
(buffy coats). B cell antigen presenting function was assessed using multiple cell culture assays.  
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To evaluate the effect of chemotherapeutic drugs on the ability of B cells to act as APCs, we 
co-cultured T cells with B cells pretreated with the indicated chemotherapeutics or with 
untreated control cells. Since tumor specific B and T cells are scarce or absent in peripheral 
blood, the superantigen SEB, was used to enable MHC class II dependent T cell activation. We 
observed an increased lymphoblast formation and proliferation of T cells in co-cultures with 
doxorubicin pretreated B cells, suggesting that doxorubicin enhance the capacity of B cells to 
activate T cells.  
To identify the mechanism for the observed increase in T cell activation, we investigated 
aspects of all the three signals required for an APC to activate a T cell. To this end, we first 
analyzed the expression of MHC class II (HLA-DR) and the co-stimulatory molecules 
CD80/86 respectively on B cells treated with doxorubicin in vitro. There was no upregulation 
of HLA-DR suggesting that signal 1 is unaffected by doxorubicin. However, the CD86 
expression was elevated in treated B cells, implying that doxorubicin reinforce  
co-stimulation, i.e. signal 2, providing additional help for activating T cells, as we could 
demonstrate. 
We further demonstrated a causative link between the observed increase in CD86 expression 
and the increased CD4+ T lymphoblast formation, since CD86 blockage restored T cell 
activation, thus corroborating the notion of doxorubicin to potentiate immune responses via 
signal two reinforcement. Moreover, in our cytokine profiling, we disclosed that doxorubicin 
decreased the secretion of IL-10 and TNF-α, cytokines with immunosuppressive effects, 
suggesting an effect also on signal three. In addition, we proposed a thwarting effect of 
doxorubicin on both immunosuppressive Tregs and Bregs as we noted a decrease in IL-2 and 
of intracellular IL-10. This finding conforms to a nature paper, where Shalapour et al. reported 
that CD8+ T cell dependent anti-tumor effects of chemotherapy were potentiated by the 
elimination of mouse Bregs (256). Finally, CD86 expression was increased on circulating B 
cells of patients treated with doxorubicin-containing NAC, establishing an in vivo relevance of 
our findings. 
In sum, we show that doxorubicin can enhance the antigen presenting ability of human B cells 
and this effect is mediated by increased expression of a co-stimulatory molecule and an altered 
cytokine profile. Our findings are in line with our previous reports on cisplatin to augment the 
immune stimulatory activity of DC differentiating human monocytes (226) and of  
Antigen-dependent clonal expansion of B cells infiltrating human bladder tumors (242). 
The multiple assays utilized strengthen this study and the conclusions drawn. However, we do 
acknowledge some limitations. For instance, the respective cell types were pretreated with 
chemotherapeutics separately and then co-cultured with an untreated cell type. Naturally, this 
is dissimilar to the in vivo situation and in hindsight, additional samples with mixed cells during 
treatment would have added value to the study. However, the in vivo increase of CD86 
expression in NAC treated patients supports the mechanisms being operative also in patients. 
Moreover, the study size of fifteen patients with an incomplete sample set warrants for larger 
studies to validate the findings.  
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Effective tumor antigen presentation is crucial in order to evoke a clinically relevant anticancer 
immune response. Thus, if the here reported effects could be maximized, for example by 
refining doxorubicin containing chemotherapy regimens, patient outcome may be improved. 
Perhaps most significant, our data could be useful in the major efforts currently devoted to 
develop combinatorial regimens that harness the immunostimulatory effects of chemotherapy 
to boost immunotherapy. In this endeavor, detailed knowledge of what effect chemotherapy 
has on the immune system is fundamental.  
Our results suggested an indirect effect of doxorubicin on Tregs that warrants further 
investigation, preferably on Treg frequency and function since we observed cytokine 
alterations crucial for these aspects. Moreover, to further support therapeutic targeting of B 
cell-mediated T cell activation, studies addressing the effect of doxorubicin on B cells’ impact 
on T cell activation per se, i.e. on the magnitude of the intrinsic T cell activation signaling 
pathway, would be of value.  
To conclude, our data show that chemotherapeutic drugs can enhance the antigen presenting 
ability of human B cells, which is useful knowledge in the pursuit of improving patient response 
to cancer therapy, may it be chemotherapy alone or in combination with immunotherapy. 
4.3 NEOADJUVANT CHEMOTHERAPY REINFORCES THE ANTI-TUMOR  
T CELL RESPONSE IN UROTHELIAL URINARY BLADDER CANCER  
(PAPER III) 
At the time when this study (paper III) was initiated, the notion that certain chemotherapies 
have immunostimulatory effects was well substantiated. However, somewhat surprising, only 
a few studies had described such effects on T cells in the setting of human solid cancers. One 
such example was a report of cisplatin to both increase the Teff cell to Treg ratio and to reduce 
Treg immunosuppressive activity in peripheral blood of non-small cell lung cancer patients 
(257). These results were congruent with our findings of chemotherapy to elicit B cell-mediated 
effects on both Tregs and T effs (paper II). Shifting focus to the T cell arm of the AIS, we also 
changed scenery from peripheral blood to the SN. This is a key site for the induction of tumor-
specific Teff responses, a concept which is fundamental for the groups’ overarching research 
idea.  
On that basis, we aimed to elucidate the effect of NAC on the composition and phenotypes of 
T cells from the SN. We further determined how these effects correlate to pathological NAC 
response and to the number of received treatment cycles.  
Patients (n=40) diagnosed with MIBC were prospectively included. Out of these, 27 patients 
underwent NAC and 13 patients were NAC-naïve. T cells from SNs and peripheral blood were 
characterized by multicolor flow cytometry and epigenetic analysis by pyrosequencing. Cell 
reactivity was investigated using an adapted FASCIA protocol.  
We found, that in NAC-patients, the expression of the exhaustion marker PD-1 was markedly 
decreased in both CD8+ and CD4+ SN-Teff cells. FACS-analysis further demonstrated that in 
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CD8+ Teff cells, the activation marker T-bet and the cytotoxic molecules granzyme B and 
perforin were all increased by NAC in a dose-dependent manner and these effects were most 
pronounced in patients with CR. In addition, CR-patients exhibited functionally committed 
CD8+ T cells, marked by hypomethylation in the PRF1 and IFNG gene loci. These findings 
indicate that NAC induces CD8+ T cell cytotoxicity in a dose-response manner and accord with 
observations in mice where chemotherapeutic agents have been demonstrated to induce CD8+ 
T cell dependent eradication of prostate cancers and lung adenocarcinoma (234, 256).  
In our evaluation of total SN T cell (CD45+CD3+ cells) frequency, an increase was observed in 
NAC patients, mainly reflecting a significant increase in the CD4+ T cell subset. The fraction 
of PD-1-expressing CD4+ Teff cells was decreased in the unstratified NAC group, similarly to 
the CD8+ T cells. However, when stratifying for response to NAC, NAC-responders had an 
increase in PD-1-expressing CD4+ Teff cells, whereas in non-responding (NR) patients, PD-1 
expression was nearly absent in the corresponding cells. These findings prompted us to further 
characterize the PD-1+ cells, which almost exclusively were CD45RO+ (mean = 94% 
CD45RO+ cells), demonstrating their antigen experience. 
In line with our findings from paper II, we found that NAC-treated patients displayed a greater 
anti-tumor reactivity in the SN-CD4+ Teff cells compared to the NAC-naïve group when 
stimulating SN-derived lymphocytes with autologous tumor homogenate. 
With regards to Tregs, we confirmed an accumulation in SNs compared to PBMC, previously 
described for other solid cancers (161). However, when stratifying for treatment, NAC-treated 
patients exhibited decreased Treg fractions in the SN compared to NAC-naïve patients. 
Additionally, this decrease followed a dose-dependent pattern as we observed significantly 
lower number of Tregs in patients receiving ≥3 NAC-cycles vs. 2 cycles. Our phenotypic 
characterization of the Treg subset, disclosed a reduced SN-Treg suppressive activity in NAC 
patients, marked by a decreased expression of HLA-DR, PD-1, and the inhibitory molecule 
CD39. In agreement, the decrease of CD39+ or CD69+ Tregs was most pronounced in patients 
with CR. Altogether, these findings indicate that NAC-treatment has an opposite effect on Treg 
frequency and function, compared to CD8+ and CD4+ Teff cells. This is in accordance with a 
noticeable amount of reports on chemotherapies to abrogate immunosuppressive cellular 
networks in patients with various malignancies including non–small-cell lung- (257), 
pancreatic- (258) and colorectal cancer (216). The many reports on this type of indirect 
immunostimulation, suggest that suppressive cells may be more sensitive to cytotoxic drugs 
than immune effector cells.  
Finally, we investigated if the relation between SN bulk CD4+ Teff cell frequency and the 
frequency of Treg subpopulations correlated to NAC-response. The bulk CD4+ Teff cells/bulk 
Treg ratio did not correlate to NAC-response. However, when relating CD4+ Teff frequency 
specifically to Tregs expressing the suppressive marker CD39 or the activation marker CD69, 
we observed that patients with CR displayed an increased ratio of CD4+ Teff cells to the number 
of Tregs expressing these markers. The data suggests that clinical outcome is better predicted 
based on phenotypical data rather than the sole frequency of T cell subsets in the TME. Such 
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data also serve as a reminder of the complexity of tumor immunology research, comprising a 
plethora of immune cell subsets that presumably stand in constant dynamic phenotypical 
change in response to cues in the TME, enabled by a postulated high degree of plasticity.  
In aggregate, we revealed considerable stimulatory effects of NAC on the phenotype, function 
and epigenetic regulation of SN T cells in MIBC patients. These effects were both direct, i.e. 
stimulation of immune effector cells, and indirect, i.e. inhibition of immunosuppressive cells. 
As acknowledged in the appended paper, the major limitation of this study was that NAC-naïve 
patients were not NAC-eligible, and thus was not a fully matched control group. Another 
limitation is that the other commonly used, Gemcitabine-Cisplatin, NAC regimen and its 
putative immune effects, were not investigated (except for in one patient), limiting the 
applicability of the data.  
This report, of NAC to promote SN anti-tumor T cell immunity, urge for novel refined 
chemotherapy protocols, aiming to maximize these effects in the treatment of MIBC. A tailored 
approach may be successful, as indicated by the notable inter-patient variability with regard to 
these effects within the NAC group. The exact predictive markers that could be used for 
tailoring chemotherapy regimens remain to be identified. In this effort, the markers and adapted 
FASCIA method used in this study might be useful. Adapted protocols to optimize the use of 
NAC alone would also pave the way for the development of protocols which yields synergistic 
effects of NAC and immunotherapy in combination.  
Furthermore, we hope that this study – with data on both PD-1 expression and tumor-specific 
reactivity, might be used in the pursuit to find biomarkers that predict response to checkpoint 
inhibitors. On this subject, we noted in our data that overall, the reported positive T cell effects 
were nearly absent in patients with no histopathologic response. Additionally, in these (NR) 
patients, PD-1 expressing CD4+ T effs were absent. We imagine that, collectively, these results 
reflect a reduced immunogenic effect of NAC that follows with the limited cytotoxic effect of 
the chemotherapy in NR-patients. In turn, this lack of immunogenicity, hinder CD4+ T eff 
activation as well as exhaustion, explaining the absence of PD-1 expression.  
Along such lines of thoughts, strategies to increase patient response to checkpoint blockers has 
been developed and proven successful on a pre-clinical level. For instance, Pfirschke et al. 
demonstrated that immunogenic chemotherapeutics can induce a T cell response through 
increased adjuvanticity mediated by enhanced TLR4 signaling, and that this response can be 
harnessed to sensitize lung adenocarcinomas to immune checkpoint therapy (234). 
To clinically apply such knowledge, the main tumor-specific factors determining patient 
response to chemotherapy (and other standard cancer therapies with immune effects) and the 
concomitant tumor-immunogenicity needs to be identified for individual cancer types and 
subtypes. If the key factors would be identified and pharmacologically targeted, a boosting 
effect could, hypothetically, be achieved for all ”on target” immune effects of cancer therapies. 
Naturally, this is an ongoing, challenging, endeavor throughout the field of tumor immunology. 
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4.4 IL-16 PROCESSING IN SENTINEL NODE TREGS IS A FACTOR IN  
TUMOR IMMUNITY (PAPER IV)  
The presence of immune suppressive circuits in the SN is well known. In this context Tregs 
have been proposed to play a central role, but the suppressive signaling pathways employed by 
this population are poorly understood likewise the mechanism utilized by tumor cells to 
instigate such SN immune tolerance. We have demonstrated the SN as a promising source to 
harness T cells for the use in ACTs (143) and detailed understanding of inhibitory networks 
would enable optimization of such treatment. Furthermore, our findings in study III did imply 
a negative role of SN Tregs as opposed to the protective role for tumor-derived Tregs 
demonstrated in study I.  
These somewhat conflicting findings and incomplete understanding framed the initial idea for 
this study that aimed to explore if the proteome in SN-resident T cells is altered by the tumor 
and to identify key proteins in SN T cell signaling, focusing on Tregs. To this end, MIBC 
patients were prospectively included along with healthy donors. At cystectomy, SNs, non-SNs 
(nSNs) and peripheral blood samples were collected. Proteomics, flow cytometry and 
immunoblotting assays were conducted. 
In our initial analysis, we found that protein expression is generally increased in both SN and 
nSN derived Tregs compared to peripheral blood whereas for Teff cells the opposite was found, 
with a reduced protein expression in SN Teff cells. These findings suggest a selective 
stimulatory effect of tumor-derived factors on Tregs and an inhibitory effect on T effs in tumor 
associated lymph nodes. Alternatively, this could be explained by a physiological higher 
immune regulating activity in lymph nodes than in peripheral blood. Network enrichment 
analysis enabled clarification on this matter as we found that growth- and immune signaling 
pathways are specifically up-regulated in SN Tregs, suggesting an active role of these cells in 
the SN of MIBC patients. This finding is in congruence with a recent report of pre-metastatic, 
immunosuppressive, changes in regional lymph nodes of prostate cancer, demonstrated in a 
mouse model (259) and is also in line with studies of other malignancies demonstrating a 
suppressive impact and increased frequency of Tregs in the SN (260, 261). 
Based on centrality analysis, we identified the cytokine IL-16 to be central in SN-Treg specific 
signaling and an increased IL-16 protein expression was further validated by flow cytometry. 
We were quite surprised by this finding, considering the infrequent reports of IL-16 function 
in Tregs. However, a few functions of IL-16 relevant to Tregs have been previously described 
and include expansion of CD4+CD25+ T cells in long-term cultures with IL-2, de novo 
induction of FOXP3 and preferential induction of the migration of  
CD4+CD25+CTLA-4+ T cells. 
IL-16 is mainly produced in T-cells. It is produced as a precursor protein that, following 
cleavage by Caspase 3, yields two biologically active proteins; a mature form comprising the 
14 kDa C-terminal part which is secreted as a tetramer, and an N-terminal part, referred to as 
pro-IL-16 (262). Mature IL-16 is a CD4 co-receptor specific ligand which is secreted during 
inflammatory responses, and it has been suggested to act as a growth- and differentiation factor 
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and as a chemoattractant. In contrast, pro-IL-16 is a growth repressor that translocate to the 
nucleus. In addition to these physiological functions, IL-16 has been implicated in several 
malignancies. Kovacs et al. reported on increased levels of IL-16 in sera of patients with 
various late-stage cancers, including bladder cancer (263). Moreover, IL-16 polymorphisms 
have been linked to several types of cancers, such as cutaneous T cell lymphoma and CRC 
(264).  
In our attempt to further delineate IL-16 SN Treg function, we probed for the two cleavage 
products by immunoblotting and found a considerably higher ratio of mature IL-16 to precursor 
IL-16 in these cells. This finding was replicated in a controlled system in which Tregs were 
cultured with tumor supernatant. Since IL-16 processing only occurs upon activation of 
Caspase-3 in CD4+ T cells (262), these findings indicated such an impact of a tumor-derived 
factor on SN Tregs. Indeed, when assessing Caspase-3 activation in Tregs cultured with tumor 
supernatant, we observed an increase compared to the medium control.  
In summary, we here profiled the proteome of SN Tregs and found growth- and immune 
signaling to be up-regulated. Most significantly, IL-16 was predicted to be central in SN Treg 
signaling, a finding validated in subsequent experiments. Furthermore, direct contact with 
tumoral factors increased active Caspase 3 and concomitant alterations in IL-16 processing. 
This is, to our knowledge, the first study to map the Treg proteome in human lymph nodes. 
Naturally, since only two patients were profiled and the sample size was small also in the 
subsequent experiments, the study should be considered as a proof of concept. We demonstrate 
that mass spectrometry can be a useful tool to identify what pathway changes that have 
occurred in TME-resident immune cell subsets. For this approach to be clinically applicable, 
proteome changes in relevant immune cell types would need to be mapped in large-scale 
proteomic studies on MIBC patients, with a long-term follow-up. With these points addressed, 
this approach could be used to i) identify predictive biomarkers for response to already existing 
cancer immunotherapies, ii) to counteract resistance development to immunotherapies and iii) 
to identify novel proteins that could be targeted in order to circumvent tumor immune escape 
which would increase the efficacy of immunotherapies like the SN-based ACT developed by 
our group.  
We propose that IL-16 represent such a target, albeit this notion remains to be validated in a 
larger patient series. Future studies also need to identify the tumor-derived molecule(s) that 
activate Caspase-3 and address their downstream effects and impact on Treg function. 
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5 CONCLUDING REMARKS AND FUTURE PERSPECTIVE 
In patients with urinary bladder cancer, the tumor-immune system interaction is active, with a 
clearly altered lymphocyte infiltrate (summarized in Figure 5). This finding aligns with the 
consensus view of this malignancy to be immunogenic and suitable to target with 
immunotherapy. During the last decade, immunotherapy has proven an effective therapeutic 
approach in various cancers but the rapid pace of both clinical and preclinical studies within 
the field has also helped to define three major remaining challenges: i) To evoke a directed 
immune response against a (non-tolerogenic) neoantigen, ii) To render this immune response 
sizeable and iii) durable. 
It is being increasingly recognized that standard chemotherapy may significantly enhance 
anticancer immune responses in people with cancer (225). This thesis supports this notion, 
since substantial stimulatory effects of NAC on the phenotypes and functions of SN T cells and 
on circulating B cells in patients with advanced bladder cancer were observed. Furthermore, 
our finding of an increased tumor-specific reactivity after NAC treatment imply an increased 
exposure of neoantigens and thus relates to the pursuit of overcoming the first  challenge, where 
an optimized NAC regimen appears beneficial. This idea fits with the common mechanistic 
model of the positive immune effects to partly result from an increased tumor immunogenicity, 
which chemotherapeutics elicits by inducing a certain manner to die, namely through a so 
called immunogenic cell death (ICD) (225). 
Our observation that patients without tumor downstaging did not demonstrate these positive 
immune effects imply a linkage between these effects and the direct cytotoxic effect of NAC 
on the tumor cells. It is key to resolve the causal relation here, because if these tumors are 
refractory to chemotherapy because of a lack of stimulatory immune effects and not vice versa, 
it would suggest that the cancer cells have developed intrinsic resistance mechanisms to 
specifically escape the immunogenic effects of chemotherapy. Such scenario is plausible, given 
the recent recognition of cancer cell intrinsic oncogenic pathways to frequently involve 
immune escape mechanisms (151). An obvious such candidate to examine in a future study 
would be ICD pathways, where mutations in, for instance, eIF2α, hypothetically could 
constitute such an oncogenic, “escape through drug resistance” mechanism. Theoretically, 
targeting of such pathways could extend the beneficial immunogenic chemotherapy effects and 
perhaps turn non-responders to responders. 
The increased tumor immunogenicity induced by chemotherapy can be harnessed through the 
combinatory use with checkpoint blockade (234). Such ongoing efforts of developing 
combinatory treatment protocols represent promising approaches to overcome the second 
challenge. This thesis has contributed also in this endeavor. Specifically, we hope our data on 
PD-1 expression and tumor-specific reactivity may be useful in the effort of finding biomarkers 
predicting who would benefit from combination therapies. On a more general level, we have 
demonstrated a profound context-dependency of lymphocyte function in the TME. It appears 
that a given immune cell may play different roles even within a single tumor and its 
microenvironment, in which leukocytes are irregularly distributed. The spatial distribution, 
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together with an array of factors regarding the organization of the leukocyte infiltrate of the 
tumor, adds up to the ”immune contexture”. This is a useful concept because, if properly 
assessed, it yields information relevant to prognosis and may predict response to 
immunotherapies. Our findings of the Treg role to differ between the tumors’ central part, 
invasive front and sentinel node, advances the framework of this concept. In the sentinel node, 
a negative role was indicated by our observation of a shifted balance favoring Teff cells over 
activated Tregs in complete responders to NAC. We also observed a sentinel node-specific 
alteration of the Treg proteome, where IL-16 signaling was prominent, suggesting proteomic 
analysis of separate sentinel node cell populations as a useful complementary tool for the 
exploration of the immune contexture. Taken together, these findings may contribute in the 
early efforts of crafting a platform to provide guidance in treatment decisions on personalized 
immunotherapies. 
A critical question within the field of oncoimmunology is: What are Tregs regulating in cancer? 
This thesis provides the answer that, in UBC tumor tissue, Tregs suppress tumor-promoting 
inflammation, which may at least in part explain the favorable prognosis associated to Treg 
tumor-infiltration in this cancer. Perhaps most importantly, the finding gives a more nuanced 
comprehension of the role of Tregs in tumor immunity at large which hopefully will provide 
guidance in the clinical use of immunotherapies targeting these cells (which include checkpoint 
blockers) in people with cancer (162). In inflammation-driven cancers, boosting the Treg-
MMP2 axis rather than Treg depletion appears as a potential therapeutic target.  
Although the responses to checkpoint blockade are often durable, complete tumor eradication 
is only rarely seen (4). This fact highlights the importance of the third challenge – to induce 
long-lasting memory responses, establishing a sizeable pool of potent tumor antigen specific  
T cells residing in the TME. This might be achieved by further additional drug combinations 
targeting distinct aspects of tumor immunity, including drugs counteracting T cell exhaustion. 
A promising such attempt is IDO-inhibition combined with PD-1 blockade in an ongoing trial 
for patients with MIBC (265).  
The complexity of the immune system is both a blessing and a curse for our species. To 
constrain the immunosubversive effects casted by tumors, the “onco” and “immunology must 
be brought closer together, for us to get the full picture of this intricate interplay. Along those 
lines, examining the immune contexture of the emerging bladder cancer taxonomies, which are 
based on molecular footprints (266), would provide knowledge of the basic cellular 
mechanisms of cancer immunity, and perhaps also point on targets enabling to nip tumor 
immune evasion in the bud. 
 
 
 
 
 
 
 
  67 
 
 
 
Figure 5. Thesis summary. The major findings from each of the included papers are illustrated. 
Arrows indicate the direction of the demonstrated effects exerted by a cell type or by 
Doxorubicin-containing chemotherapy. In paper I, we found Tregs to suppress tumor 
invasiveness through inhibiting the production of the ECM-degrading enzyme MMP2, in both 
M2 macrophages and UBC cells. Paper II uncovers a stimulatory effect of chemotherapy on 
the antigen presenting ability of B cells, mediated partly through an increased co-stimulation 
and with a subsequent increased activation of CD4+ T cells. In paper III, we demonstrated that 
chemotherapy treatment promotes T effector functions in the sentinel node, manifested by an 
increased tumor-specific reactivity in CD4+ Teffs and, in CD8+ Teffs, by an increased 
expression of the cytotoxic Granzyme B and Perforin molecules and a decreased exhaustion. 
Paper IV reveals a substantial tumoral impact on the proteome of sentinel node Tregs with an 
altered IL-16 signaling and processing, mediated by tumor factors inducing caspase-3 in these 
cells. Figure courtesy of Malin Winerdal. 
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6 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Tesen om att immunförsvaret har förmågan att skydda mot tumörers utveckling kan spåras 
ända tillbaks till 1800 talet, men tog lång tid att vetenskapligt bekräfta. Idag är existensen av 
detta viktiga skydd helt uppenbar, inte minst på grund av ett flertal nya immunterapier som 
under de senaste decennierna haft en succéartad framgång. Dessa behandlingar ger varaktiga 
skydd, ibland till och med botar patienter, mot cancrar där det tidigare inte fanns några medel 
att ta till. Hur kommer det sig då att tumörer ändå, i så pass stor omfattning, utvecklas och att 
så många drabbas av cancer? För att förstå det måste man först förstå hur immunsystemet 
försvarar oss mot denna sjuka. 
Förenklat kan man säga att cancerceller utvecklas till följd av förändringar i sin arvsmassa, 
DNA. Dessa förändringar kan ge upphov till så kallade tumörantigen, det vill säga proteiner 
som till viss del är kroppsfrämmande, vilket innebär en möjlighet för immunförsvaret att känna 
igen, och i många fall eliminera dessa förvandlade celler. Dessvärre har många tumörer 
utvecklat strategier för att undvika igenkänning eller för att på andra sätt undslippa 
immunförsvarets attack Dessa strategier, som gemensamt brukar kallas escape-mechanisms, 
eller flyktkmekanismer, är en del av svaret på frågan. Den givna följdfrågan blir då: Hur 
åstadkommer tumören denna igenkänningsflykt? För att förstå det måste man först förstå hur 
immunsystemet gör för att särskilja kroppsegna från kroppsfrämmande celler. 
Det är en stor utmaning för immunsystemet att, å ena sidan vara ett effektivt skydd mot yttre 
faror som exempelvis bakterier, medan å andra sidan inte angripa kroppsegna vävnader och 
orsaka så kallad autoimmunitet. För att lösa denna uppgift, att upprätthålla tolerans, används 
bland annat Regulatoriska T celler (Tregs). Tregs är en typ av immunceller som reglerar 
tolerans genom att hämma andra typer av immunceller, exempelvis T effektor celler (Teffs) 
och B celler. Samtliga dessa celler tillhör det specifika adaptiva immunsystemet. En strategi 
som tumörer använder för att undslippa en immunattack är att ”tjuvkoppla” Tregs, som då, i 
stället för att skydda mot autoimmunitet, skyddar tumören från det övriga immunsystemet, det 
vill säga den (tumören) ”lurar” immunsystemet att den är kroppsegen.  
I det här arbetet avhandlas den intrikata interaktionen mellan tumören och nämnda celltyper i 
patienter med urinblåsecancer (UBC). Vi studerade även vilken påverkan kemoterapi, ibland 
benämnt som ”cellgifter”, har på denna process.  
Det första arbetet tog avstamp i en föregående studie där vi sett att tumör-infiltrerande Tregs 
korrelerade till en gynnsam prognos vid UBC. Det var något förvånande eftersom Tregs 
generellt anses vara negativa för prognos enligt ovan beskrivna logik. Vi hade använt proteinet 
FOXP3 för att identifiera Tregs, vilket inte är en fullständigt specifik markör. För att bekräfta 
att vi inte hade misstagit Tregs för en annan celltyp, gjorde vi en djupgående analys av tumör-
infiltrerande, FOXP3-uttryckande celler. Vi kunde visa på att dessa celler uppfyllde 
karaktärsmässiga, funktionella och epigenetiska (vilket kort kan beskrivas som förändringar på 
men inte i DNA) definitioner på Tregs, vi hade alltså klassificerat dem korrekt. Som nästa steg 
återstod då att kunna förklara varför Tregs är gynnsamma för prognos vid UBC. En ledtråd 
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gavs från andra rapporter med motsvarande resultat för vissa andra, specifika cancertyper. 
Gemensamt för dessa cancrar är en uttalad inflammation, som anses kunna driva på 
cancerutveckling. Vi fokuserade därför på inflammatoriska signalvägar och fann att Tregs 
kunde hämma produktionen av MMP2, ett enzym som kan öka tumörens invasiva förmåga, i 
både inflammatoriska celler (makrofager) och i UBC-celler belägna vid den invasiva fronten 
av tumörens närmiljö. Vår förklaringsmodell är därför att Tregs, genom dessas anti-
inflammatoriska effekt, kan gynna patienter med inflammatoriskt drivna cancrar.  
Tvärtemot en vanlig uppfattning om att kemoterapier är förödande för immunsystemet, finns 
det nu en stor medvetenhet kring att deras effektivitet delvis beror på en positiv effekt på 
immunsystemets attack mot tumören. I vår föresats att undersöka effekterna av kemoterapi på 
celler tillhörande det adaptiva immunförsvaret, började vi med att undersöka B celler i perifert 
blod i friska donatorer, men även i patienter med UBC. Vi fann att doxorubicin, en standard 
kemoterapi för ett flertal cancertyper, har en stimulerande effekt på B cellers förmåga att 
presentera ovan nämnda tumörantigen till Teff celler. Detta ledde till att dessa Teff celler i 
större utsträckning aktiverades och initierade en attack specifikt riktad mot tumören. Ett sätt 
för immunceller att kommunicera med varandra är genom att utsöndra cytokiner, vilka är 
signalmolekyler som kan ha antingen en stimulerande eller hämmande effekt. I denna studie 
fann vi att doxorubicin minskade B cellers produktion av hämmande cytokiner, vilket indikerar 
även en indirekt positiv effekt på T cellsaktivering, genom att skapa en mer stimulerande 
cytokinsignalering.  
I våra fortsatta undersökningar kring immuneffekter av kemoterapi fokuserade vi på T celler 
och bytte från att undersöka blod till att istället undersöka lymfknutor i tumörens närmiljö, 
fortfarande från patienter med UBC. Vi kunde då se att, precis som i föregående studie, så 
ökade kemoterapi CD4+ Teff cellers tumörspecifika aktivering även i lymfknuta. CD8+ Teff 
celler, en cytotoxisk subtyp av T celler, det vill säga celler med kapacitet att direkt döda 
tumörceller, fick en ökad sådan cytotoxisk profil och uppvisade i lägre utsträckning tecken på 
utmattning. När vi specifikt tittade på de patienter som svarade allra bäst på kemoterapi, såg vi 
att deras CD8+ Teff celler, uppvisade tydliga tecken, bland annat epigenetiska sådana, till att 
potent kunna eliminera cancerceller. Däremot var situationen annorlunda, faktiskt helt motsatt, 
vad gällde Tregs. Vi observerade att ju fler kemoterapikurer en patient fått, desto lägre andel 
Tregs fanns i lymfknutorna och, det fåtal som fanns där, visade tecken på nedsatt funktion, 
jämfört med patienter som inte fått kemoterapi. Slutligen, när vi undersökte sammansättningen 
av de olika typerna av immunceller, visade det sig att de som svarat bäst på kemoterapi hade 
den mest gynnsamma cellkompositionen för en effektiv immunattack mot tumören.  
I avhandlingens sista arbete fortsatte vi att undersöka T celler i tumör-associerade lymfknutor, 
men vi undersökte nu hela proteomet, det vill säga samtliga proteiner som vid 
undersökningstillfället uttrycks i den givna cellpopulationen. Vi undrade om tumören 
påverkade proteomet i Tregs och jämförde därför proteinuttrycket i Tregs från 
tumördränerande lymfknutorna med Tregs från lymfknutor som inte dränerar tumören. Det 
visade sig att proteiner som är involverade i direkt immunologiska funktioner var ökade och, 
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mest förvånande, att cytokinen IL-16 var en central signalmolekyl i Tregs från 
tumördränerande lymfknutor. Eftersom det endast finns ett fåtal rapporter om funktionen av 
IL-16 i Tregs, gjorde vi ytterligare analyser och kunde då se att direkt kontakt med 
tumörfaktorer ökade modifieringen av IL-16 molekylen till sin aktiva form. Slutligen kunde vi 
identifiera ett enzym, caspase-3, som vi tror förmedlar denna modifiering. Vidare studier 
behövs för att utröna den funktionella betydelsen av dessa fynd.  
Sammanfattningsvis påvisar dessa studier utpräglade förändringar av det adaptiva 
immunsystemet i tumörens närmiljö i patienter med UBC. På denna process, har kemoterapi 
en tydligt positiv effekt. Våra fynd, av bland annat nya tumörbiologiska funktioner av Tregs, 
ger ökade detaljkunskaper inom det onkoimmunologiska fältet som förhoppningsvis kan 
användas för att hitta nya strategier att frigöra det immunsvar som lamslagits av tumören. 
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